Transcriptomic and phenotypic analysis of murine embryonic stem cell derived BMP2+ lineage cells: an insight into mesodermal patterning by Doss, Michael Xavier et al.
Genome Biology 2007, 8:R184
Open Access 2007 Doss et al. Volume 8, Issue 9, Article R184 Research
Transcriptomic and phenotypic analysis of murine embryonic stem 
cell derived BMP2+ lineage cells: an insight into mesodermal 
patterning
Michael Xavier Doss*, Shuhua Chen*, Johannes Winkler*, Rita Hippler-
Altenburg*, Margareta Odenthal†, Claudia Wickenhauser†, 
Sridevi Balaraman†, Herbert Schulz‡, Oliver Hummel‡, Norbert Hübner‡, 
Nandini Ghosh-Choudhury§, Isaia Sotiriadou*, Jürgen Hescheler* and 
Agapios Sachinidis*
Addresses: *Institute of Neurophysiology, University of Cologne, Robert-Koch Str. 39, 50931 Cologne, Germany. †Institute of Pathology, 
University of Cologne, Joseph-Stelzmann-Str. 9, 50931 Cologne, Germany. ‡Max-Delbrueck-Center for Molecular Medicine - MDC, Robert-
Rössle Str. 10, 13092 Berlin, Germany. §Department of Pathology, The University of Texas Health Science Center at San Antonio, TX 78229, 
USA. 
Correspondence: Agapios Sachinidis. Email: a.sachinidis@uni-koeln.de
© 2007 Doss et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transcriptome and phenotype of BMP2+ cells <p>Transcriptome analysis of BMP2<sup>+ </sup>cells in comparison to the undifferentiated BMP2 ES cells and the control population  from 7-day old embryoid bodies led to the identification of 479 specifically upregulated and 193 downregulated transcripts.</p>
Abstract
Background: Bone morphogenetic protein (BMP)2 is a late mesodermal marker expressed during vertebrate
development and plays a crucial role in early embryonic development. The nature of the BMP2-expressing cells
during the early stages of embryonic development, their transcriptome and cell phenotypes developed from these
cells have not yet been characterized.
Results:  We generated a transgenic BMP2 embryonic stem (ES) cell lineage expressing both puromycin
acetyltransferase and enhanced green fluorescent protein (EGFP) driven by the BMP2 promoter. Puromycin
resistant and EGFP positive BMP2+ cells with a purity of over 93% were isolated. Complete transcriptome analysis
of BMP2+ cells in comparison to the undifferentiated ES cells and the control population from seven-day-old
embryoid bodies (EBs; intersection of genes differentially expressed between undifferentiated ES cells and BMP2+
EBs as well as differentially expressed between seven-day-old control EBs and BMP2+ EBs by t-test, p < 0.01, fold
change >2) by microarray analysis led to identification of 479 specifically upregulated and 193 downregulated
transcripts. Transcription factors, apoptosis promoting factors and other signaling molecules involved in early
embryonic development are mainly upregulated in BMP2+ cells. Long-term differentiation of the BMP2+ cells
resulted in neural crest stem cells (NCSCs), smooth muscle cells, epithelial-like cells, neuronal-like cells,
osteoblasts and monocytes. Interestingly, development of cardiomyocytes from the BMP2+ cells requires
secondary EB formation.
Conclusion: This is the first study to identify the complete transcriptome of BMP2+ cells and cell phenotypes
from a mesodermal origin, thus offering an insight into the role of BMP2+ cells during embryonic developmental
processes in vivo.
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Background
Bone morphogenetic protein (BMP)2 is a member of the
transforming growth factor (TGF)-β superfamily and plays a
crucial role in early embryonic patterning as shown by gene
ablation studies [1,2]. It is normally expressed in lateral plate
mesoderm and extraembryonic mesoderm [1,3]. BMP2+ mes-
odermal cells at this stage comprise a subset of mesoderm,
the lateral plate cardiogenic mesoderm [4]. BMP2 expression
immediately follows the transient expression of T-Brachyury
in the nascent mesoderm. Interestingly, administration of
soluble BMP2 to chick embryo explant cultures induces full
cardiac differentiation in stage 5-7 anterior medial meso-
derm, a tissue that is normally not cardiogenic [5].
Since BMP2 is a cardiogenic factor as well as expressed in the
cardiogenic mesoderm, it is highly imperative to investigate
the molecular nature and phenotype of the mesodermal cells
expressing BMP2 during the early stages of development in
the context of cardiomyogenesis. Also, it has been well docu-
mented that BMP2 is a potent apoptotic inducer and a potent
neurotrophic factor, acting on target cells in a concentration
gradient-dependant manner, mostly through its paracrine
mode of action [6-8]. Thus, BMP2 plays a pivotal role not only
during cardiomyogenesis but also during other early embry-
onic patterning and lineage specification. To date, the molec-
ular nature and phenotype of the mesodermal cells
expressing BMP2 during the early stages of development
have not been characterized, leaving a gap in our understand-
ing of their molecular interactions with target cells and, thus,
their role during early embryonic patterning and cell lineage
commitment. This is due, in part, to the pleiotrophic effects of
BMP2 and largely because of the practical difficulty in isolat-
ing pure early stage BMP2-expressing cells in sufficient quan-
tities during early embryonic development in vivo. Extensive
investigations applying the in vitro embryonic stem (ES) cell-
based developmental model in the past two decades have
proven its value for the elucidation of developmental proc-
esses during embryonic development, in particular, the
mechanisms by which lineage commitment occurs during
early embryogenesis [9].
To circumvent the practical difficulties in the isolation of
BMP2-expressing cells in sufficient quantities during embry-
onic development in vivo, and to address the molecular
nature and behaviour of the BMP2+ mesodermal cells during
their differentiation into specific somatic cell lineages, we
first established an ES cell-derived transgenic BMP2 cell lin-
eage expressing both puromycin acetyltransferase and
enhanced green fluorescent protein (EGFP) under the control
of the BMP2 promoter. In order to identify all possible signal
transduction pathways and biological processes characteris-
tic of the BMP2+ cells, we performed expression studies using
Affymetrix microarrays. Our study on the phenotypic identi-
fication of the ES cell-derived BMP2 lineage-specific cells
shows that the early BMP2+ population contained a heteroge-
neous population of predominantly NCSCs and their lineages
- smooth muscle cells, epithelial like cells, astrocytes and
melanocytes. When the early BMP2+ population was further
cultured under certain conditions, it contained cardiomyo-
cytes, macrophages and osteoblasts. Interestingly, these are
the cell phenotypes that need BMP2 for their phenotypic
induction. Our work clearly demonstrates the presence of a
multi-lineage progenitor phenotype resembling NCSCs cells
in early ES cell-derived BMP2+ cells. Moreover, identification
of the key signal transduction pathways induced or repressed
in BMP2+ cells explains the observed potential of BMP2 in
modulating early embryonic development, in particular the
mesodermal patterning.
Results and discussion
Isolation of BMP2+ cells from the transgenic BMP2 ES 
cell lineage
The transgenic BMP2 ES cell lineage was generated with the
linearized pBMP2p-puro IRES2 EGFP construct by stable
transfection. Like its parental wild type CGR8, the BMP2 ES
cells do not express BMP2 in the undifferentiated state (Fig-
ure 1a(i) and 1a(ii)). Expression of BMP2 during progressive
differentiation induced by the hanging drop protocol (see
Materials and methods) starts in the three-day-old embryoid
bodies (EBs), gradually increases to a maximum in the five-
day-old EBs and, thereafter, gradually decreases to a mini-
mum in ten-day-old EBs, in the same manner as that seen in
the RT-PCR results (Figure 1a). During the course of differen-
tiation induced by the hanging drop protocol, the EGFP-
expressing cells in the three- and four-day-old EBs were
found to be scattered (Figure 1b). As differentiation contin-
ues, the EGFP fluorescence peaks in the five-day-old EBs and
the EGFP-expressing cells are localized to a particular region
in every EB, as shown in Figure 1b. The RNAs isolated from
these EBs were analyzed for the expression of other candidate
markers (T-bra, flk1, smooth muscle α-actin, neurofilament-
Expression pattern of BMP2 in differentiating EBs Figure 1 (see following page)
Expression pattern of BMP2 in differentiating EBs. (a) Detection of the expression of BMP2 by qPCR on the samples from EBs derived from wild-type 
CGR8 ES cells (i) and RT-PCR (ii) on samples from EBs derived from BMP2 ES cells (for conditions, see Additional data file 14). The qPCR results are 
presented as the mean of three independent experiments ± standard deviation. (b) Expression of EGFP during differentiation of the BMP2 ES cells induced 
by the conventional hanging drop protocol. Scale bar represents 50 μm. (c) Protocol for isolation of puromycin resistant BMP2+ cells after treating the 
plated four-day-old EBs with 3 μg/ml puromycin for three days. (d,e) FACS analysis of the trypsinized untreated control and puromycin resistant BMP2+ 
cells. (f) BMP2+, three days after plating in gelatine-coated tissue culture dishes in the presence of 3 μg/ml puromycin. Scale bar represents 50 μm. (g,h) 
Detection of BMP2 in BMP2+ cells (g) or ES cells (h) by immunohistochemistry staining. Stainings were done after the cells were trypsinized and plated on 
microscopic slides for 24 hours. Scale bar represents 20 μm.http://genomebiology.com/2007/8/9/R184 Genome Biology 2007,     Volume 8, Issue 9, Article R184       Doss et al. R184.3
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Figure 1 (see legend on previous page)
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H (NF-H) and also α-fetoprotein (AFP)) to demonstrate that
these EBs were differentiating in the normal way as per their
parental wild-type EBs (Additional data file 1). Isolation and
further characterization of the BMP2+, puromycin-resistant
cells were optimized according to the protocol described in
Figure 1c. Briefly, a single cell suspension of BMP2+ ES cells
was seeded in bacteriological dishes for two days to form two-
day-old EBs. These were then transferred into gelatine coated
tissue culture dishes and cultured for a further two days.
Thereafter, plated EBs were treated with 3 μg/ml puromycin
for three days. After trypsinization of puromycin-resistant
seven-day-old BMP2+ cells, fluorescence-activated cell sort-
ing (FACS) analysis was performed. As demonstrated in Fig-
ure 1d,e, after 3 days of puromycin treatment, EGFP
fluorescing and puromycin resistant BMP2+ cells (hereafter
called BMP2+ cells) accounted for 93% of the cells in the EBs,
whereas in the control EBs without puromycin treatment
(hereafter called control EBs (seven-day-old EBs)) only 11%
of the cells were BMP2+ cells. This result demonstrates a
nearly 8.5-fold enrichment of BMP2+ cells in EBs treated with
puromycin. As demonstrated in Figure 1f, plating of the
BMP2+  cells in gelatine coated tissue culture dishes for
another three days in the presence of puromycin results in a
bright EGFP-positive BMP2+ cell population. Furthermore,
the BMP2 protein was detected by immunostaining using
BMP2-specific antibodies. The undifferentiated BMP2 ES
cells were included as a negative control (Figure 1h). As dem-
onstrated, BMP2 is detected only in the cytosol, and specifi-
cally in vesicles, of the BMP2+ cells (Figure 1g).
Functional categorization of transcripts upregulated in 
BMP2+ cells
The Affymetrix data obtained were validated by quantitative
real time PCR (qPCR; Additional data file 2). To identify Gene
Ontology (GO) [10] categories, Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathways [11] and BioCarta pathways
[12] specifically enriched in BMP2+ cells, we first analyzed
genes that are upregulated in BMP2+ cells in comparison to
control EBs. Moreover, to identify BMP2+ cell-specific genes,
a three condition comparative analysis of the BMP2+ cells to
control EBs and to BMP2 ES cells was made (Tables 1 and 2).
Table 1 indicates different GO terms (level 5) and one KEGG
pathway (mitogen-activated protein kinase (MAPK) signaling
pathway) that are enriched in the BMP2+ cells compared to
control EBs. In the GO categories 'biological process'
(GOTERM_BP), 'molecular function' (GOTERM_MF) and
'cellular component' (GOTERM_CC), several relevant cate-
gories are pooled, such as transcriptional processes (for zinc
ion binding and transcription) and apoptotic processes (for
apoptosis, cell death, death, programmed cell death and reg-
ulation of apoptosis) (Table 1). Genes for transcriptional
activity and associated with apoptosis are also found to be
specifically enriched in the BMP2+ cells (Table 2). These
results suggest that BMP2 causes direct or indirect induction
of apoptotic processes. This hypothesis is supported by the
observations that apoptotic effects of BMP2 promote cavita-
tion in EBs and in mouse embryos [13]. The MAPK signaling
pathway involved in apoptotic processes [14] seems to be spe-
cific for the BMP2+ cell population (Table 2). It is well estab-
lished that the MAPK signaling pathway is involved in several
processes, including cell cycle progression, cellular transfor-
mation apoptosis and differentiation (for a review, see [14]).
These results suggest that both apoptosis and transcription
genes are characteristic gene expression signatures for the
BMP2+ cells.
Additional data files 3-5 list all the genes and include the
change factor (CF) values belonging to the GO categories
'transcription' and 'apoptosis' and the KEGG 'MAPK path-
way', respectively. Among genes highly upregulated specifi-
cally in the BMP2+ cells, Gm397 (gene model 397) and Tbx4
are identified (Additional data file 3). Tbx4 has been shown to
be expressed in the lateral mesoderm and is involved in limb
outgrowth in the mouse [15] whereas the function of Gm397
is unknown.
Interestingly, among the MAPKs, several kinases belonging
to both the classical and the c-Jun amino-terminal kinase
(JNK) and p38 MAP kinase pathway were overexpressed in
BMP2+ cells (Additional data file 5, KEGG pathway scheme).
The JNK and p38 MAPK pathway is known to be stimulated
by serum and stress factors [14]. The most striking gene spe-
cifically upregulated in BMP2+ cells was Hspa1a (heat shock
protein 1A; Additional data file 5), which belongs to the
Hsp70 family of stress response genes. Members of this fam-
ily participate in the process of folding and refolding of mis-
folded proteins and in the transport of proteins across
membranes [16]. Hsp1a is also found to be upregulated in
chondrons, which includes the chondrocyte and its pericellu-
lar matrix, compared to chondrocytes [17].
Table 3 lists the developmental genes that are overexpressed
in the BMP2+ cells compared to control EBs. Among these,
Dnmt3l  (DNA (cytosine-5-)-methyltransferase,3-like),  Fgf4
(fibroblast growth factor 4), Tdgf1 (teratocarcinoma derived
growth factor), Zic1 (zinc finger protein of the cerebellum 1),
Ifrd1  (interferon-related developmental regulator 1), Tbx4
(T-Box 4), and Neurod1 (neurogenic differentiation 1) were
highly expressed in the BMP2+ cells. DNA methylation of the
genome is essential for mammalian development and plays
crucial roles in a variety of biological processes including
genomic imprinting [18,19]. Dnmt3lmat-/-  mice die before
mid-gestation due to an imprinting defect [18]. In addition,
Dnmt3L is required for differentiation in the extra-embryonic
tissue [18]. Molecular and genetic data indicate that FGF sig-
naling plays a major role in regulating trophoblast prolifera-
tion and differentiation [20]. Fgf4  is expressed in early
embryos, becoming restricted to the inner cell mass (ICM) of
the blastocyst and later to the epiblast of the early post-
implantation embryo [20].http://genomebiology.com/2007/8/9/R184 Genome Biology 2007,     Volume 8, Issue 9, Article R184       Doss et al. R184.5
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Table 1
Functional annotations enriched among genes upregulated* in BMP2+ cells compared to control cells in seven-day-old EBs
Category Term Count p value
GOTERM_MF_5 Zinc ion binding 142 3.2E-16
GOTERM_CC_5 Nucleus 279 3.6E-12
GOTERM_BP_5 Transcription 128 2.5E-10
GOTERM_BP_5 Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism 121 5.5E-9
GOTERM_BP_5 Cellular protein metabolism 147 4.9E-8
GOTERM_MF_5 Binding 143 2.9E-7
GOTERM_MF_5 Metal ion binding 61 6.8E-7
GOTERM_MF_5 Transition metal ion binding 74 4.1E-6
GOTERM_MF_5 Cation binding 74 4.6E-6
GOTERM_MF_5 Ion binding 74 4.6E-6
GOTERM_BP_5 Biopolymer modification 83 1.3E-5
GOTERM_BP_5 Response to unfolded protein 12 2.5E-5
GOTERM_MF_5 ATP binding 84 6.8E-5
GOTERM_BP_5 Apoptosis 38 1.2E-4
GOTERM_CC_5 Intracellular membrane-bound organelle 225 2.4E-4
GOTERM_CC_5 Membrane-bound organelle 225 2.4E-4
GOTERM_BP_5 Regulation of protein kinase activity 12 3.1E-4
GOTERM_MF_5 Protein kinase activity 44 4.9E-4
KEGG_PATHWAY MAPK signaling pathway 24 7.1E-4
GOTERM_BP_5 Nucleobase, nucleoside, nucleotide and nucleic acid metabolism 18 1.7E-3
GOTERM_BP_5 Regulation of programmed cell death 24 1.9E-3
GOTERM_CC_5 Intracellular 244 3.3E-3
GOTERM_BP_5 Response to protein stimulus 6 3.4E-3
GOTERM_CC_5 Vacuole 17 3.4E-3
GOTERM_BP_5 Phosphate metabolism 45 3.7E-3
GOTERM_BP_5 Cell death 16 4.1E-3
GOTERM_BP_5 Death 16 4.1E-3
GOTERM_BP_5 Programmed cell death 16 4.1E-3
GOTERM_BP_5 Negative regulation of cellular metabolism 17 5.6E-3
BIOCARTA The information-processing pathway at the IFN-β enhancer 4 6.2E-3
GOTERM_BP_5 Regulation of apoptosis 22 6.7E-3
GOTERM_BP_5 Protein kinase cascade 17 6.8E-3
GOTERM_BP_5 Embryonic development 15 7.2E-3
GOTERM_MF_5 Nucleotide binding 41 8.9E-3
GOTERM_CC_5 Intracellular organelle 243 9.0E-3
GOTERM_CC_5 Organelle 243 9.0E-3
GOTERM_BP_5 Negative regulation of progression through cell cycle 10 9.3E-3
GOTERM_BP_5 Regulation of progression through cell cycle 24 9.7E-3
GOTERM_BP_5 Positive regulation of programmed cell death 12 1.2E-2
GOTERM_BP_5 Embryonic limb morphogenesis 7 1.5E-2
GOTERM_MF_5 Pyrophosphatase activity 29 2.1E-2
BIOCARTA Regulation of transcriptional activity by PML 4 2.2E-2
GOTERM_BP_5 Cellular physiological process 112 2.3E-2
GOTERM_MF_5 Purine nucleotide binding 52 2.4E-2
GOTERM_BP_5 Embryonic development (sensu Mammalia) 7 2.7E-2
GOTERM_CC_5 Lytic vacuole 13 2.8E-2
GOTERM_BP_5 Negative regulation of protein kinase activity 5 2.8E-2
GOTERM_BP_5 Regulation of biological process 34 2.9E-2R184.6 Genome Biology 2007,     Volume 8, Issue 9, Article R184       Doss et al. http://genomebiology.com/2007/8/9/R184
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GOTERM_CC_5 Cell 256 3.0E-2
GOTERM_BP_5 Regulation of cellular process 29 3.4E-2
GOTERM_BP_5 Regulation of protein biosynthesis 9 3.8E-2
GOTERM_MF_5 Transcription cofactor activity 9 3.8E-2
GOTERM_MF_5 Transcription factor binding 9 4.0E-2
GOTERM_BP_5 Negative regulation of programmed cell death 9 4.2E-2
GOTERM_BP_5 Protein catabolism 13 4.2E-2
GOTERM_BP_5 Regulation of gene expression, epigenetic 3 4.2E-2
GOTERM_MF_5 Protein kinase binding 6 4.3E-2
GOTERM_BP_5 Primary metabolism 35 4.5E-2
GOTERM_BP_5 RNA metabolism 22 4.5E-2
GOTERM_BP_5 Regulation of cellular biosynthesis 9 4.7E-2
GOTERM_MF_5 Guanyl nucleotide binding 14 4.8E-2
GOTERM_BP_5 Reproduction 11 4.8E-2
GOTERM_BP_5 Response to abiotic stimulus 13 4.8E-2
GOTERM_BP_5 Gene silencing 4 5.0E-2
KEGG_PATHWAY Pantothenate and CoA biosynthesis 4 5.0E-2
GOTERM_BP_5 Physiological process 127 5.1E-2
GOTERM_BP_5 Bone resorption 3 5.2E-2
GOTERM_MF_5 Cysteine-type peptidase activity 9 5.2E-2
GOTERM_MF_5 Ligase activity 17 5.4E-2
GOTERM_BP_5 Response to chemical stimulus 11 5.4E-2
GOTERM_BP_5 Regulation of bone remodeling 4 5.6E-2
GOTERM_BP_5 Biopolymer catabolism 13 6.1E-2
KEGG_PATHWAY Nitrogen metabolism 4 6.3E-2
GOTERM_BP_5 ER-nuclear signaling pathway 3 6.4E-2
GOTERM_BP_5 Regulation of protein metabolism 13 6.4E-2
GOTERM_CC_5 Nucleolus 12 7.1E-2
GOTERM_BP_5 Protein biosynthesis 30 7.3E-2
GOTERM_MF_5 Transcription corepressor activity 6 7.3E-2
GOTERM_BP_5 Intracellular receptor-mediated signaling pathway 3 7.6E-2
GOTERM_MF_5 Transcription regulator activity 9 7.7E-2
GOTERM_BP_5 Macromolecule biosynthesis 33 8.0E-2
GOTERM_BP_5 Positive regulation of cell proliferation 9 8.1E-2
GOTERM_BP_5 Embryonic hemopoiesis 2 8.2E-2
GOTERM_BP_5 Posttranscriptional gene silencing 2 8.2E-2
GOTERM_BP_5 RNA-mediated gene silencing 2 8.2E-2
GOTERM_BP_5 RNA-mediated posttranscriptional gene silencing 2 8.2E-2
GOTERM_MF_5 Glutaminase activity 2 8.4E-2
GOTERM_MF_5 Ubiquitin-protein ligase activity 16 8.4E-2
GOTERM_BP_5 Eye development 5 8.6E-2
BIOCARTA Eukaryotic protein translation 3 9.0E-2
GOTERM_BP_5 Amino acid transport 6 9.1E-2
GOTERM_BP_5 Positive regulation of cell activation 5 9.2E-2
GOTERM_BP_5 Development 37 9.3E-2
*Change fold >2, Student's t-test p value < 0.01. Count indicates the number of genes in the functional annotation category. The p value is from gene 
enrichment in annotation terms calculated by the Fisher's exact t-test.
Table 1 (Continued)
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Teratocarcinoma-derived growth factor (encoded by Tdgf1,
also known as Cripto-1) plays a pivotal role as a multifunc-
tional modulator during embryogenesis and oncogenesis, and
may be involved in stem cell maintenance [21]. NeuroD1 is a
member of the basic helix-loop-helix transcription factor
family and has been shown to play a major role in develop-
ment of the nervous system and formation of the endocrine
system [22]. The transcription factor ZIC1 plays important
roles in patterning the neural plate in early vertebrate devel-
opment. Zic1 expression was detected in the neural plate bor-
der, dorsal neural tube, and somites [23]. Moreover, Zic1
plays an important role in early patterning of the Xenopus
presumptive neurectoderm [24].
Interferon-related developmental regulator 1 (IFRD1; also
known as PC4, Tis7) is a chromatin-associated protein that
induces chromatin condensation and plays multiple roles in
cellular processes, including transcription, DNA replication
and repair [25]. It is expressed early in the mouse embryo and
extra-embryonic tissues during gastrulation and at mid-ges-
tation in restricted structures (such as the central nervous
system, kidney, and lung primordia), whereas it is
ubiquitously expressed at late gestation [26]. IFRD1 has been
shown to act as a coactivator of myogenic differentiation 1
(MyoD1) and myocyte enhancer factor 2C (MEF2C) during
myogenesis [27].
The three condition comparative analysis results in a set of
seven BMP2+ cell-specific genes (Table 4). Among these, the
most prominently regulated genes are Zic1, Ifrd1 and Tbx4,
which have been discussed previously. Ciliary neurotrophic
factor (CNTF) is of particular interest. CNTF is a cytokine
with neurotrophic and differentiating effects on central nerv-
ous system cells and myotrophic effects on skeletal muscle
[28].
GO enrichment analysis of the genes downregulated in 
BMP2+ cells
To identify overrepresented GO categories or KEGG path-
ways specifically downregulated in BMP2+ cells, we analyzed
Table 2
Functional annotations enriched among genes upregulated* in BMP2+ cells compared to control cells in seven-day-old EBs and undiffer-
entiated BMP2 ES cells
Category Term Count p value
GOTERM_MF_5 Zinc ion binding 46 5.6E-5
GOTERM_CC_5 Nucleus 95 3.3E-4
GOTERM_BP_5 Cellular protein metabolism 66 3.3E-4
GOTERM_BP_5 Protein catabolism 10 4.9E-3
GOTERM_BP_5 Apoptosis 17 5.9E-3
GOTERM_BP_5 Biopolymer modification 38 6.0E-3
GOTERM_BP_5 Biopolymer catabolism 10 6.9E-3
GOTERM_BP_5 Positive regulation of programmed cell death 8 9.1E-3
GOTERM_MF_5 ATP binding 30 1.4E-2
GOTERM_BP_5 Response to unfolded protein 5 1.5E-2
GOTERM_BP_5 Transcription 47 1.5E-2
GOTERM_BP_5 Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism 45 2.7E-2
GOTERM_BP_5 Regulation of programmed cell death 11 3.8E-2
GOTERM_BP_5 Regulation of progression through cell cycle 11 5.1E-2
GOTERM_BP_5 Protein kinase cascade 8 5.3E-2
GOTERM_BP_5 Regulation of protein kinase activity 5 5.6E-2
GOTERM_BP_5 Small GTPase mediated signal transduction 9 5.6E-2
GOTERM_BP_5 Post replication repair 2 6.2E-2
GOTERM_MF_5 Ubiquitin-protein ligase activity 8 6.2E-2
GOTERM_BP_5 Regulation of apoptosis 10 7.4E-2
GOTERM_BP_5 Protein transport 16 7.5E-2
GOTERM_MF_5 Protein kinase activity 15 8.3E-2
KEGG_REACTION Phytoceramide+h2o<=>fattyacid+phytosphingosine 3 8.7E-2
GOTERM_CC_5 Lytic vacuole 6 8.8E-2
KEGG_PATHWAY MAPK signaling pathway 9 9.5E-2
*Change fold >2, Student's t-test p value < 0.01. Count indicates the number of genes in the functional annotation category. The p value is from gene 
enrichment in annotation terms calculated by the Fisher's exact t-test.R184.8 Genome Biology 2007,     Volume 8, Issue 9, Article R184       Doss et al. http://genomebiology.com/2007/8/9/R184
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the data with the DAVID bioinformatics resource [29]. Com-
parative analysis of the expression level of genes in BMP2+
and in control EBs shows downregulated genes belong to sev-
eral overrepresented GO categories, such as focal adhesion,
TGF-β signaling pathway, extracellular matrix (ECM)-recep-
tor interaction and shh signaling pathway (Table 5). Some
overrepresented categories are related to the developmental
processes (for example, development, organ development,
embryonic development and brain development; (Table 5,
entries in bold). This is not surprising, since the seven-day-
old control EBs can still develop into various somatic precur-
sor cells, as indicated in the tables (for example, vasculature
development and brain development). Notably, GO catego-
ries associated with impaired developmental processes
appear not to be characteristic of BMP2+  cells when the
expression levels of these genes in undifferentiated ES cells
are also taken into account. These results clearly show that
the BMP2+  cells are more closely related to the
undifferentiated ES cells than to the control EBs with regard
to their developmental potential and plasticity.
Table 3
Genes of GO category 'development' upregulated at least two-fold* in BMP2+ cells compared to control cells in seven-day-old EBs
Affymetrix ID Gene name Fold change
1425035_s_at dna (cytosine-5-)-methyltransferase 3-like 14.0
1420086_x_at fibroblast growth factor 4 9.4
1450989_at teratocarcinoma-derived growth factor 9.0
1423477_at zinc finger protein of the cerebellum 1 7.5
1416067_at interferon-related developmental regulator 1 7.0
1456033_at t-box 4 6.8
1426412_at neurogenic differentiation 1 5.7
1418640_at sir2 alpha 4.3
1456341_a_at kruppel-like factor 9 4.1
1424607_a_at xanthine dehydrogenase 3.7
1452240_at bruno-like 4, rna binding protein (drosophila)3 . 7
1452179_at phd finger protein 17 3.6
1416455_a_at crystallin, alpha b 3.5
1416953_at connective tissue growth factor 3.2
1428334_at osteopetrosis associated transmembrane protein 1 3.1
1418901_at ccaat/enhancer binding protein (c/ebp), beta 2.8
1421151_a_at eph receptor a2 2.8
1422556_at guanine nucleotide binding protein, alpha 13 2.7
1434009_at glucocorticoid receptor dna binding factor 1 2.6
1434054_at v-maf musculoaponeurotic fibrosarcoma oncogene family, protein g (avian)2 . 5
1422057_at nodal 2.5
1436164_at solute carrier family 30 (zinc transporter), member 1 2.5
1422033_a_at ciliary neurotrophic factor 2.5
1449949_a_at coxsackievirus and adenovirus receptor 2.5
1433455_at linker of t-cell receptor pathways 2.5
1425932_a_at cug triplet repeat, rna binding protein 1 2.4
1451383_a_at conserved helix-loop-helix ubiquitous kinase 2.4
1455222_a_at upstream binding protein 1 2.4
1451257_at acyl-coa synthetase long-chain family member 6 2.4
1426858_at inhibin beta-b 2.3
1421624_a_at enabled homolog (drosophila) 2.3
1437540_at mucolipin 3 2.3
1429192_at sloan-kettering viral oncogene homolog 2.2
1452438_s_at taf4a rna polymerase ii, tata box binding protein (tbp)-associated factor 2.2
1436907_at neuron navigator 1 2.1
1450986_at nucleolar protein 5 2.0
1416904_at muscleblind-like 1 (drosophila) 2.0
*Student's t-test, p value < 0.01.http://genomebiology.com/2007/8/9/R184 Genome Biology 2007,     Volume 8, Issue 9, Article R184       Doss et al. R184.9
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Genes belonging to GO categories related to the proliferative
processes, such as M phase of mitotic cycle and DNA
metabolism are specifically downregulated in the BMP2+
cells. Additional data files 6-8 list the genes belonging to the
GO 'development' category, TGF-β KEGG pathway and the
GO 'M phase' category. The most strikingly downregulated
genes from the TGF-β KEGG pathway (Additional data file 7)
are Bmp5, Fst (follistatin), Id1 (inhibitor of DNA binding 1)
and Tgfβ2 (TGF-β). BMPs are members of the TGF-β super-
family of signal molecules, which mediate many diverse bio-
logical processes ranging from early embryonic tissue
patterning to postnatal tissue homeostasis [30]. WNT, Notch,
FGF, Hedgehog and BMP signaling pathways act together
during embryogenesis, tissue regeneration and carcinogene-
sis [31]. Follistatin is a BMP antagonist that regulates the
actions of the TGF-β superfamily members [32].
Selected GO biological process annotations of genes 
differentially expressed in BMP2+ cells
We analyzed those transcripts that are differentially
expressed in BMP2+ cells and involved in selected GO catego-
ries of the 'biological process' branch (Additional data file 9).
SOURCE [33] was used to obtain GO annotations for the cat-
egory 'biological process'. The Genesis GO browser (version
1.7.0) [34,35] was used to identify transcripts of interest
belonging to the biological process categories adhesion, cell
cycle, cell death, cell-cell signaling, cellular metabolism,
development, stress response, signal transduction, transcrip-
tion, and transport. Numbers of these transcripts for each
selected category are displayed as separate up- and downreg-
ulated groups (Additional data file 9, parts B and D).
More stress-related and less developmental genes are identi-
fied when the gene expression levels in undifferentiated ES
cells are taken into account ('three condition comparative
analysis') than when expression levels are compared between
BMP2+ cells and control cells alone (pairwise comparison). In
the three condition comparative analysis, all 16 cell death-
related transcripts are upregulated in BMP2+ cells. When
analyzed further, most of them are apoptosis-related genes.
This annotation suggests that cell death during ES cell differ-
entiation mainly involves apoptosis. When ES cells are not
taken into account in the two condition comparison, some (18
out of 49) cell death transcripts are downregulated in BMP2+
cells. In reference to signal transduction during BMP2+ cell
differentiation, more transcripts are differentially upregu-
lated than downregulated in BMP2+ cells compared to ES
cells and control EBs. However, the ratio is reversed when
BMP2+ cells are compared only with control EBs. The control
EBs differentiat to various cell populations and, thus, more
signaling pathways are activated than in BMP2+ cells, which
eventually contribute to signaling pathways limited to
development.
Hierarchical clustering of genes identified as differentially
expressed and involved in development in the pairwise com-
parison illustrates how transcripts distribute into co-regu-
lated groups and show good reproducibility between
experimental replicates (Additional data file 9, part E). Inter-
estingly, the experimental conditions 'BMP2+  cells' and
'undifferentiated cells' are more closely related to each other
than to the condition 'control EBs', indicating an earlier
developmental stage of BMP2+ cells compared to control EBs
of the same age (Additional data file 9, part E).
Expression of genes in the BMP2+ cells associated with 
plasticity, and mesodermal and NCSC phenotypes
BMP2+ cells are still in a state of plasticity
BMP2+ cells significantly upregulate Oct4 and Nanog tran-
script expression compared to the control EBs, in which sev-
eral somatic cell types develop (Figure 2a,b), but at a level
lower than ES cells. This implies that there are some
populations of BMP2+ cells with multi-lineage progenitor
phenotypes, which are still in a certain state of plasticity and
can give rise to different cell fates depending upon the stimuli.
This is further confirmed by the upregulated expression of
leukemia inhibitory factor (LIF) in the BMP2+ population
compared to the control EBs. Interestingly, the transcripts of
Activin, Nodal and Cripto are also upregulated in the BMP2+
population compared to the control EBs. Recently, it has been
demonstrated that the TGF-β/Activin/Nodal signaling path-
way is necessary for the maintenance of pluripotency in ES
Table 4
Genes of GO category 'development' upregulated at least two-fold* in BMP2+ cells compared to control cells in seven-day-old EBs and 
undifferentiated BMP2 ES cells
Affymetrix ID Gene name Fold change BMP2+ versus BMP2 EBs Fold change BMP2+ versus BMP2 ES cells
1423477_at zinc finger protein of the cerebellum 1 7.5 8.8
1416067_at interferon-related developmental regulator 1 77 . 1
1456033_at T-box 4 6.8 6.4
1434009_at RIKEN cDNA 6430596G11 gene 2.6 3.4
1422033_a_at ciliary neurotrophic factor 2.5 3.2
1425932_a_at CUG triplet repeat, RNA binding protein 1 2.4 2.5
1416904_at muscleblind-like 1 (Drosophila)2 2 . 7
*Student's t-test, p value < 0.01.R184.10 Genome Biology 2007,     Volume 8, Issue 9, Article R184       Doss et al. http://genomebiology.com/2007/8/9/R184
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Table 5
Functional annotations (GO, KEGG, Biocarta) enriched in transcripts downregulated* in BMP2+ cells compared to control cells in seven-
day-old EBs
Category Term Count p value
GOTERM_BP_5 Development 82 3.6E-20
GOTERM_BP_5 Organ development 57 5.1E-19
GOTERM_BP_5 Morphogenesis 56 1.6E-16
GOTERM_BP_5 Cell differentiation 37 2.1E-11
GOTERM_BP_5 Blood vessel morphogenesis 25 1.7E-10
GOTERM_BP_5 Embryonic development 25 1.2E-8
GOTERM_BP_5 System development 30 1.9E-8
GOTERM_BP_5 Organ morphogenesis 27 2.3E-8
GOTERM_BP_5 Vasculature development 17 2.8E-8
GOTERM_BP_5 Tube development 18 5.8E-8
GOTERM_BP_5 Enzyme linked receptor protein signaling pathway 27 6.1E-8
GOTERM_BP_5 Cell migration 28 1.0E-7
GOTERM_BP_5 Blood vessel development 16 1.3E-7
GOTERM_BP_5 Nervous system development 25 5.5E-7
GOTERM_BP_5 Embryonic limb morphogenesis 12 1.8E-6
GOTERM_BP_5 Angiogenesis 17 3.7E-6
GOTERM_BP_5 Embryonic morphogenesis 14 6.7E-6
GOTERM_BP_5 Cell motility 21 7.3E-6
GOTERM_BP_5 Locomotion 21 8.7E-6
GOTERM_BP_5 Localization of cell 21 8.7E-6
GOTERM_BP_5 Neuron differentiation 24 1.1E-5
GOTERM_BP_5 Steroid biosynthesis 12 1.2E-5
GOTERM_BP_5 Brain development 16 1.9E-5
GOTERM_BP_5 Cell development 15 2.0E-5
GOTERM_BP_5 Alcohol catabolism 11 3.2E-5
GOTERM_BP_5 Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism 100 3.3E-5
GOTERM_BP_5 Tissue development 12 6.8E-5
GOTERM_BP_5 Axon guidance 12 6.8E-5
GOTERM_BP_5 Tube morphogenesis 10 7.1E-5
GOTERM_BP_5 Central nervous system development 10 8.5E-5
GOTERM_BP_5 Lipid biosynthesis 20 9.8E-5
GOTERM_BP_5 Monosaccharide metabolism 15 1.1E-4
GOTERM_BP_5 Regulation of biological process 41 1.4E-4
GOTERM_BP_5 Ossification 12 1.5E-4
GOTERM_BP_5 Transcription 99 1.6E-4
GOTERM_BP_5 Carbohydrate catabolism 11 2.2E-4
GOTERM_CC_5 Cell 203 2.6E-4
GOTERM_BP_5 Neural crest cell development 6 2.7E-4
GOTERM_BP_5 Regulation of development 11 2.9E-4
GOTERM_BP_5 Regulation of cellular process 35 3.1E-4
GOTERM_BP_5 DNA metabolism 34 3.4E-4
GOTERM_BP_5 Neuron morphogenesis during differentiation 16 3.4E-4
GOTERM_BP_5 Cellular macromolecule catabolism 21 3.5E-4
GOTERM_BP_5 Branching morphogenesis of a tube 7 4.1E-4
GOTERM_BP_5 Morphogenesis of a branching structure 7 4.1E-4
GOTERM_BP_5 Neurogenesis 15 4.3E-4
GOTERM_CC_5 Anchored to plasma membrane 5 4.8E-4http://genomebiology.com/2007/8/9/R184 Genome Biology 2007,     Volume 8, Issue 9, Article R184       Doss et al. R184.11
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GOTERM_CC_5 Anchored to membrane 5 4.8E-4
GOTERM_BP_5 Cellular morphogenesis during differentiation 17 4.9E-4
GOTERM_BP_5 Pattern specification 10 4.9E-4
GOTERM_BP_5 Skeletal development 8 5.0E-4
GOTERM_BP_5 Limb morphogenesis 7 6.2E-4
GOTERM_BP_5 Appendage morphogenesis 7 6.2E-4
GOTERM_BP_5 Appendage development 7 6.2E-4
GOTERM_BP_5 Regulation of cell differentiation 9 8.5E-4
GOTERM_BP_5 Patterning of blood vessels 6 8.5E-4
GOTERM_BP_5 Vasculogenesis 6 8.5E-4
GOTERM_BP_5 Regulation of myeloid cell differentiation 4 1.1E-3
GOTERM_BP_5 Cellular carbohydrate metabolism 21 1.2E-3
GOTERM_BP_5 Neural crest cell migration 5 1.2E-3
GOTERM_BP_5 Steroid metabolism 14 1.5E-3
KEGG_PATHWAY Focal adhesion 25 1.5E-3
KEGG_PATHWAY TGF-β signaling pathway 14 1.7E-3
GOTERM_BP_5 Exocrine system development 4 1.8E-3
GOTERM_BP_5 Salivary gland morphogenesis 4 1.8E-3
GOTERM_BP_5 Salivary gland development 4 1.8E-3
GOTERM_BP_5 Negative regulation of cell differentiation 6 2.0E-3
KEGG_PATHWAY ECM-receptor interaction 14 2.1E-3
GOTERM_BP_5 Biomineral formation 7 2.1E-3
GOTERM_BP_5 Ureteric bud branching 5 2.2E-3
GOTERM_CC_5 Intracellular 183 2.3E-3
GOTERM_BP_5 Negative regulation of signal transduction 10 2.3E-3
GOTERM_MF_5 Heparin binding 8 2.4E-3
GOTERM_BP_5 Ureteric bud development 6 2.5E-3
GOTERM_BP_5 Lung development 7 2.9E-3
GOTERM_BP_5 Gland development 4 2.9E-3
GOTERM_BP_5 Mesenchymal cell differentiation 5 2.9E-3
GOTERM_BP_5 Mesenchymal cell development 5 2.9E-3
KEGG_PATHWAY Hedgehog signaling pathway 10 3.4E-3
GOTERM_BP_5 Embryonic appendage morphogenesis 6 3.5E-3
GOTERM_BP_5 Embryonic development (sensu Metazoa) 10 3.6E-3
GOTERM_BP_5 Bone remodeling 7 4.9E-3
GOTERM_BP_5 Alcohol biosynthesis 6 4.9E-3
GOTERM_BP_5 Negative regulation of development 6 4.9E-3
GOTERM_MF_5 Nucleic acid binding 8 5.4E-3
GOTERM_CC_5 Transcription factor complex 28 5.4E-3
KEGG_PATHWAY Glycolysis/gluconeogenesis 10 5.7E-3
GOTERM_BP_5 Neural crest cell differentiation 4 5.8E-3
GOTERM_BP_5 Cartilage development 4 5.8E-3
GOTERM_BP_5 Cartilage condensation 4 5.8E-3
GOTERM_BP_5 Axonogenesis 8 5.9E-3
GOTERM_BP_5 Tissue remodeling 7 6.2E-3
GOTERM_BP_5 Regulation of cell migration 7 6.2E-3
GOTERM_BP_5 Neurite morphogenesis 8 6.5E-3
GOTERM_BP_5 Sterol metabolism 8 6.5E-3
GOTERM_BP_5 Cellular morphogenesis 14 7.0E-3
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GOTERM_BP_5 Regulation of physiological process 28 7.0E-3
GOTERM_BP_5 Positive regulation of cellular metabolism 18 7.5E-3
GOTERM_BP_5 Regulation of cell motility 7 7.7E-3
GOTERM_BP_5 Hindlimb morphogenesis 4 7.7E-3
GOTERM_BP_5 Carboxylic acid metabolism 27 8.0E-3
GOTERM_BP_5 Carbohydrate biosynthesis 9 8.1E-3
GOTERM_BP_5 Somitogenesis 5 8.1E-3
GOTERM_BP_5 Hemopoiesis 7 8.6E-3
GOTERM_BP_5 Hemopoietic or lymphoid organ development 7 9.5E-3
GOTERM_BP_5 Regulation of cellular physiological process 24 9.6E-3
GOTERM_BP_5 Neuron development 8 1.0E-2
GOTERM_BP_5 Respiratory tube development 6 1.1E-2
GOTERM_BP_5 Embryonic pattern specification 5 1.1E-2
GOTERM_BP_5 Metanephros development 6 1.2E-2
GOTERM_BP_5 Cellular lipid metabolism 26 1.3E-2
GOTERM_BP_5 Anterior/posterior pattern formation 5 1.3E-2
GOTERM_BP_5 Protein complex assembly 11 1.5E-2
KEGG_PATHWAY Pentose phosphate pathway 6 1.5E-2
GOTERM_CC_5 Organelle 179 1.5E-2
GOTERM_CC_5 Intracellular organelle 179 1.5E-2
GOTERM_BP_5 Glial cell differentiation 4 1.6E-2
GOTERM_BP_5 Wnt receptor signaling pathway 10 1.6E-2
GOTERM_CC_5 Membrane-bound organelle 157 1.8E-2
GOTERM_CC_5 Intracellular membrane-bound organelle 157 1.8E-2
GOTERM_MF_5 Catalytic activity 63 1.9E-2
BIOCARTA Pertussis toxin-insensitive CCR5 signaling in macrophage 5 2.0E-2
GOTERM_BP_5 Genitalia morphogenesis 3 2.1E-2
GOTERM_BP_5 Placenta development 3 2.1E-2
GOTERM_CC_5 Nucleoplasm 31 2.1E-2
GOTERM_MF_5 Iron ion binding 16 2.1E-2
GOTERM_BP_5 Positive regulation of biological process 12 2.1E-2
GOTERM_BP_5 Odontogenesis 4 2.3E-2
GOTERM_BP_5 Positive regulation of cell proliferation 10 2.4E-2
KEGG_PATHWAY Axon guidance 15 2.5E-2
GOTERM_BP_5 Positive regulation of cellular process 10 2.7E-2
GOTERM_BP_5 Embryonic placenta development 3 2.8E-2
GOTERM_BP_5 Cell proliferation 11 2.8E-2
GOTERM_BP_5 Negative regulation of cellular process 11 3.0E-2
GOTERM_BP_5 Inner ear morphogenesis 5 3.1E-2
GOTERM_BP_5 Negative regulation of biological process 12 3.2E-2
GOTERM_BP_5 Base-excision repair 4 3.6E-2
GOTERM_BP_5 Negative regulation of neuron differentiation 3 3.7E-2
GOTERM_MF_5 DNA N-glycosylase activity 3 3.7E-2
KEGG_PATHWAY Fructose and mannose metabolism 8 3.8E-2
GOTERM_BP_5 Amino acid derivative metabolism 7 3.8E-2
GOTERM_CC_5 Nucleosome 7 4.1E-2
GOTERM_BP_5 Positive regulation of cellular physiological process 7 4.1E-2
GOTERM_CC_5 Chromosome 19 4.1E-2
GOTERM_MF_5 Oxidoreductase activity 11 4.2E-2
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GOTERM_BP_5 Morphogenesis of an epithelium 5 4.2E-2
GOTERM_MF_5 Protein kinase activity 27 4.6E-2
GOTERM_CC_5 Nuclear lumen 35 4.6E-2
GOTERM_BP_5 Hormone metabolism 4 4.7E-2
GOTERM_MF_5 Pyrophosphatase activity 21 4.8E-2
GOTERM_CC_5 Plasma membrane 17 5.0E-2
GOTERM_BP_5 Regulation of progression through cell cycle 20 5.0E-2
GOTERM_BP_5 Odontogenesis (sensu Vertebrata) 4 5.3E-2
GOTERM_CC_5 Membrane-bound vesicle 8 5.3E-2
GOTERM_CC_5 Vesicle 8 5.3E-2
GOTERM_CC_5 Cytoplasmic vesicle 8 5.3E-2
KEGG_PATHWAY WNT signaling pathway 15 5.5E-2
GOTERM_CC_5 Protein complex 36 5.5E-2
GOTERM_BP_5 Nucleoside metabolism 4 5.9E-2
GOTERM_BP_5 Segmentation 4 5.9E-2
GOTERM_BP_5 Morphogenesis of embryonic epithelium 4 5.9E-2
GOTERM_BP_5 Sex differentiation 5 6.0E-2
GOTERM_MF_5 Interleukin-11 receptor activity 2 6.1E-2
GOTERM_MF_5 Interleukin-11 binding 2 6.1E-2
GOTERM_CC_5 Chromatin 11 6.2E-2
GOTERM_CC_5 Heterotrimeric G-protein complex 5 6.3E-2
BIOCARTA Sonic hedgehog (shh) pathway 4 6.4E-2
GOTERM_CC_5 Cytosol 6 6.5E-2
GOTERM_BP_5 Regulation of enzyme activity 4 6.5E-2
GOTERM_CC_5 Intrinsic to Golgi membrane 4 6.6E-2
KEGG_PATHWAY Biosynthesis of steroids 4 6.8E-2
KEGG_PATHWAY Huntington's disease 5 6.8E-2
GOTERM_BP_5 Eye development 5 7.0E-2
GOTERM_BP_5 Regulation of cell proliferation 9 7.2E-2
GOTERM_BP_5 Biopolymer modification 59 7.2E-2
GOTERM_BP_5 Physiological process 117 7.2E-2
GOTERM_BP_5 Cellular physiological process 100 7.7E-2
GOTERM_BP_5 Astrocyte differentiation 2 7.7E-2
GOTERM_BP_5 Regulation of astrocyte differentiation 2 7.7E-2
GOTERM_BP_5 Mesoderm morphogenesis 3 7.8E-2
GOTERM_BP_5 Mesoderm formation 3 7.8E-2
GOTERM_BP_5 Mesoderm development 3 7.8E-2
GOTERM_BP_5 T cell activation 3 7.8E-2
GOTERM_BP_5 Embryonic heart tube development 3 7.8E-2
GOTERM_BP_5 Negative regulation of Wnt receptor signaling pathway 3 7.8E-2
GOTERM_BP_5 Negative regulation of BMP signaling pathway 3 7.8E-2
GOTERM_BP_5 M phase of mitotic cell cycle 9 7.8E-2
GOTERM_BP_5 Regulation of signal transduction 8 7.8E-2
GOTERM_BP_5 Neural plate morphogenesis 4 7.9E-2
GOTERM_BP_5 Ear morphogenesis 4 7.9E-2
GOTERM_BP_5 Ear development 4 7.9E-2
KEGG_PATHWAY Synthesis and degradation of ketone bodies 3 8.0E-2
GOTERM_BP_5 Eye development (sensu Mammalia) 5 8.6E-2
GOTERM_MF_5 Acyltransferase activity 9 8.7E-2
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cells [36]. Therefore, the increased levels of the pluripotency
associated gene markers Oct4 and Nanog might be explained,
in part, by the increased expression of LIF, Activin and Nodal
observed in the BMP2+ cells (Figure 2). It is worth mentioning
the hypothesis by Niwa et al. [37] that to maintain the undif-
ferentiated stem-cell phenotype, Oct-3/4 expression must
remain within plus or minus 50% of normal diploid expres-
sion. If Oct-3/4 expression is increased beyond the upper
threshold level, differentiation into primitive endoderm or
mesoderm is triggered. If Oct-3/4 expression is decreased,
stem cells are redirected into the trophectoderm lineage. This
partly explains the increased levels of Oct-3/4 by the BMP2+
mesodermal lineages [37].
The BMP2+ cells exhibit mesodermal characteristics
The expression levels of nodal, activin, eomesodermin, cripto
and mesoderm posterior 2 (Mesp2) was increased in BMP2+
cells whereas the expression of T-bra and Mesp1 was lower in
the BMP2+ cells compared to the control EBs (Figure 2). It has
been shown that Activin and Nodal, members of the TGF-β
superfamily, play pivotal roles in inducing and patterning
mesoderm and endoderm, as well as in regulating neurogen-
esis and left-right axis asymmetry (for a review, see [38]).
Nodal genes have been identified in numerous vertebrate spe-
cies and are expressed in specific cell types and tissues during
embryonic development [38]. Moreover, Nodal null mouse
mutants lack mesoderm. Overexpression of Nodal in mouse
ES cells leads to upregulation of mesodermal and endodermal
cell markers. These findings support the key role of Nodal for
mesoderm formation [39]. Also, it was repeatedly shown that
Activin is involved in the mesodermal pattering during Xeno-
pus embryo development [40]. Cripto is the founder member
of the Cripto/FRL-1/Cryptic (CFC) family. Cripto is expressed
in tumor tissues, and studies in the mouse have established
an essential role for cripto in the formation of precardiac mes-
oderm and differentiation into functional cardiomyocytes
[41].
The T-box gene encoding eomesodermin (Eomes) is required
for mesoderm formation and the morphogenetic movements
of gastrulation. Lack of Eomes abrogates the formation of
embryonic and extra-embryonic mesoderm [42]. It has been
shown that Eomes is specifically required for the directed
movement of cells from the epiblast into the streak in
response to mesoderm induction [42]. Interestingly, we
found a dramatically low level of T-Brachyury expression in
BMP2+ cells compared to the control EBs. This result suggests
that the BMP2+ cells represent a subset of a mesodermal pop-
ulation whose formation is nearly complete at the time of
BMP2 expression, which in turn downregulates T-Brachyury
expression. However, this hypothesis does not rule out the
possibility that the necessary signals from the non-BMP2
population to induce stronger T-Brachyury expression are
eliminated due to puromycin selection. T-Brachyury is an
essential gene for the mesoderm formation, as demonstrated
in the mouse [43]. Mesp1 and Mesp2 are basic helix-loop-
helix transcription factors that are co-expressed in the ante-
rior presomitic mesoderm just prior to somite formation in
the mouse embryo [44]. Furthermore, it has been shown that
Mesp1 has a significant role in the epithelialization of somitic
mesoderm and, therefore, it is assumed that Mesp2 is respon-
sible for the rostro-caudal patterning process itself in the
anterior presomitic mesoderm [44]. Recently, it has been
shown that Mesp1 is expressed in almost all of the precursors
of the cardiovascular system in the mouse, including the
endothelium, endocardium, myocardium and epicardium
[45]. Thus, the in vitro derived BMP2+ cells exhibit more
mesodermal characteristics. This conclusion is further sup-
ported by the derivation of most of the mesodermal tissues
and complete absence of endodermal phenotypes from these
BMP2 cells in the later stages, as described below. Interest-
ingly, Noggin, an antagonist of BMP2, is also expressed in the
BMP2+ cells at a level higher than in ES cells but lower than in
the control EBs. This contradiction might be explained on the
basis that mesodermal cells exress Noggin and its expression
is regulated by BMP2 [46,47]. Also, co-expression of Noggin
BIOCARTA Repression of pain sensation by the transcriptional regulator DREAM 3 8.7E-2
BIOCARTA IL12 and Stat4 dependent signaling pathway in Th1 development 4 8.8E-2
GOTERM_BP_5 Anatomical structure formation 3 9.0E-2
GOTERM_BP_5 Formation of primary germ layer 3 9.0E-2
GOTERM_MF_5 Bisphosphoglycerate mutase activity 2 9.0E-2
GOTERM_MF_5 Phosphoglycerate mutase activity 2 9.0E-2
GOTERM_BP_5 Phosphate metabolism 35 9.6E-2
BIOCARTA Rho-selective guanine exchange factor akap13 mediates stress fiber formation 3 9.7E-2
KEGG_PATHWAY Pyruvate metabolism 6 9.8E-2
KEGG_PATHWAY Regulation regulation of actin cytoskeleton 18 9.9E-2
*Fold change >2, Student's t-test p value < 0.01. Count indicates the number of genes in the functional annotation category. The p value is from gene 
enrichment in annotation terms calculated by the Fisher's exact t-test.
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and glial fibrillary acidic protein (GFAP) in astrocytes has
been reported [48].
BMP2+ cells lack endodermal phenotypes
Interestingly, transcripts of α-feto protein (AFP) and Sonic
hedgehog (Shh) were not detectable in BMP2+ cells (Figure
2). AFP is a marker for the endoderm-derived hepatocytes.
The expression pattern of Shh studied in several species indi-
cates that Shh is essential for endoderm-derived organ devel-
opment, such as foregut, gut, and gastrointestinal duodenal
and pancreas development [49]. Also, other gene markers for
endoderm, such as Foxa2, Hnf4a, Sox17, Transthyretin and
Gata6 [50-54], are downregulated in the BMP2+ cells. These
results show a dramatically reduced level or, more likely, the
complete absence of the endodermal cell lineage.
The BMP2+ cell lineage contains neural crest stem cells 
and their derivatives
The BMP2+ cells showed enriched expression of ectodermal
markers neurofilament (NF)-H and NF-M, but it is evident
that the BMP2+ cells shared more mesodermal characteristics
as described in the previous sections. Further investigation of
this contradictory phenomenon led to the conclusion that
these ectodermal markers may be more likely expressed by
NCSCs. In agreement with our results, it was repeatedly
reported that NCSCs share more ectodermal and less
mesodermal characteristics [55-58]. Expression of the NCSC-
specific p75NTR and Nestin transcripts at higher levels com-
pared to the control EBs (Figure 3a,b) confirmed the
increased presence of NCSCs in BMP2+ cells. In addition,
astrocyte-specific GFAP and melanocyte-specific tyrosine
Expression of pluripotent, trophectodermal, mesodermal, and endodermal gene markers in BMP2+ cells Figure 2
Expression of pluripotent, trophectodermal, mesodermal, and endodermal gene markers in BMP2+ cells. (a) RT-PCR analysis for the representative genes. 
(b-d) Relative expression level of the genes presented in (a) and additional representative genes as obtained by Affymetrix analysis. The expression levels 
of each gene were normalized with its maximum level set as 100%. Each result was an average of three independent experiments (Additional data file 13).
BMP2
+  cells
ES cells
4d EBs
7d EBs
 
(b) (a)
(c)
(d)
0
Rex1
0
BMP2
T
Eomes
Mesp1
Mesp2
Nodal
Activin
Cripto-1
0
20
40
60
80
100
120
140
Afp
Shh
Foxa2
Hnf4a
Sox17
Transthyretin
Gata6
Relative expression
Relative expression
Relative expression
Eomesodermin
T-bra
Activin
Cripto-1
BMP2
AFP
Nodal
Nanog
Oct4
Mesp1
Mesp2
GAPDH
Mash2
Cdx2
Shh
Nanog Oct4
140
120
100
80
60
40
20
120
100
80
60
40
20
ES cell
7d control EB
BMP2
+R184.16 Genome Biology 2007,     Volume 8, Issue 9, Article R184       Doss et al. http://genomebiology.com/2007/8/9/R184
Genome Biology 2007, 8:R184
phosphatase 1 (Tyrp1) in BMP2+ cells (Figure 3a) confirmed
the presence of NCSC-derived lineages in the BMP2+ lineage
as well. Expression of p75NTR in BMP2+ cells was further con-
firmed by immunostaining with an antibody against p75NTR in
BMP2+ cells (Figure 3c, left panel). Furthermore, the pres-
ence of glial cells in BMP2+ cells has been confirmed by
immunostaining with an antibody against GFAP (Figure 3c,
right panel). Notably, it has been reported that the differenti-
ation of NCSCs into their lineage fates is mainly dependant on
the presence of BMP2 at the required threshold level and also
the availability of other factors, such as TGFβ1, Wnt1, Ihh and
BMP4, in combination [56]. It was well demonstrated that
exogenous addition of recombinant BMP2 to cultured NCSCs
isolated from chicken explants of cranial and trunk dorsal
neural folds from stage 8/9 embryos resulted in the differen-
tiation of NCSC into glia, melanocytes and smooth muscle
cells [56]. Expression of smooth muscle α actin (SMA) was
also detected in the differentiated BMP2+ cells (Figure 4).
It is surprising to note that the local concentration of BMP2
secreted by BMP2+ cells themselves is able to induce the dif-
ferentiation of NCSCs into their lineages without the exoge-
nous addition of BMP2.
During vertebrate embryonic development, when the noto-
chord induces the transformation of surface ectoderm to neu-
roectoderm, a multipotential middle cell layer develops with
characteristics of both cell types. These cells are the neural
crest cells. They migrate dorsolaterally to form the neural
crest, a flattened irregular mass between the surface ecto-
derm and neuroectoderm. This layer of cells separates into
right and left portions and then migrates to various locations
within the embryo to give rise to most structures of the
peripheral nervous system, such as Schwann and glia cells of
the autonomic and enteric nervous systems, endocrine cells,
such as the adrenal medulla, and C-cells of the thyroid as well
as non-neural tissues, such as pigment cells of the skin and
Analysis of neural crest stem cell associated transcripts in BMP2+ cells Figure 3
Analysis of neural crest stem cell associated transcripts in BMP2+ cells. (a) RT-PCR analysis for the representative genes associated with NCSCs. (b) 
Relative expression level of the genes presented in (a) as obtained by Affymetrix analysis. The expression levels of each gene were normalized with its 
maximum level set as 100%. Each result is an average of three independent experiments (Additional data file 13). (c) Detection of p75 and GFAP in BMP2+ 
cells labelled by immunohistochemistry. Immunuostainings with anti-p75 (left panel) and anti-GFAP (right panel) to show the presence of NCSCs and the 
astrocytes, respectively, in BMP2+ cells one day after plating (7 + 1 days in total).
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internal organs, smooth muscle of the cardiac outflow tract
and great vessels, pericytes, craniofacial bones, cartilage and
connective tissues [59,60].
Wnt1 and c-kit are well known mediators of melanocyte dif-
ferentiation of NSCS [61,62] and are found to be expressed in
the BMP2+ population. The tyrosine kinase c-kit has been
found in the cell membranes of haematopoietic stem cells,
primordial germ cells and presumptive subepidermal
melanocytes [63]. Intriguingly, wnt-1 and BMP2 act synergis-
tically to suppress differentiation and to maintain NCSC
marker expression and multipotency by combinatorial Wnt1/
BMP2 signaling [64].
The presence of Wnt1 transcripts in the BMP2+ cell popula-
tion may be interpreted in two ways: first, Wnt1 may be
involved in the maintenance of NCSCs in their pluripotency
state in combination with BMP2; and second, Wnt1 may be
involved in driving the differentiation of NCSCs into melano-
cytes. Both possibilities cannot be ruled out in the BMP2+ cell
population since it includes proliferating NCSCs on the one
hand (increased cell number when subjected to immunos-
taining) and melanocytes in the same culture on the other
hand. The local BMP2 and/or Wnt1 gradient may drive the
NCSCs to produce smooth muscle cells, pericytes, or melano-
cytes or to remain in their pluripotent state, respectively.
This is the first study that enables us to selectively obtain ES
cell-derived NCSCs and their derivatives all at the same time
via a BMP2 promoter-based lineage selection approach. The
co-expression of Wnt1 and BMP2 indicates the existence of an
environment to both keep the NCSCs in stemness and to
enable ongoing differentiation of NCSCs to form melano-
cytes. Thus, the study of these BMP2-expressing cells during
early differentiation of ES cells will pave the way for a better
understanding of NCSCs and their differentiation into line-
ages. The BMP2+ cells derived from the ES cells may serve as
an ideal model for neural crest stem biology in the future
since the NCSCs and their derivatives can be selectively
enriched by the BMP2  promoter-driven lineage selection
approach. In addition, it provides a valuable system where the
enriched NCSCs prime themselves to differentiate into their
cell specific lineages, since the enriched NCSCs secrete BMP2
and cause a BMP2 gradient, which negates the need for sup-
plying exogenous BMP2. Noggin, an inhibitor of BMP2, can
be used to keep the NCSCs in a plastic state. Once the proce-
dures for maintaing BMP2-derived NCSCs in a state of plas-
ticity have been fine tuned, they will be potential candidates
Detection of smooth muscle cells after differentiation of the BMP2+ cells Figure 4
Detection of smooth muscle cells after differentiation of the BMP2+ cells. (a) Expression of SMA in the BMP2+ cells detected by qRT-PCR. (b) Microarray 
relative expression levels of various smooth muscle specific genes in BMP2+ cells. The expression levels of each gene were normalized with its maximum 
level set as 100%. Each result is an average of three independent experiments (Additional data file 13). (c) Detection of smooth muscle cells 1 day after 
plating the BMP2+ cells (7 + 1 days in total; top left), 8 days after plating with puromycin (7 + 8 days in total; top right), 18 days after plating with puromycin 
(7 + 18 days in total; bottom left) and 18 days after plating without puromycin (7 + 18 days in total; bottom right).
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for cell replacement therapy, since they can differentiate into
any tissue depending upon the local environment of the tissue
in which they are injected.
BMP2+ cells contain predominantly smooth muscle 
cells
As indicated in Figure 4a, expression of SMA in the BMP2+
cells is enriched compared to the control EBs. In addition, the
microarray data confirm the upregulation of SMA and other
smooth muscle specific genes, such as those encoding cal-
ponin and SM22-α, in the BMP2+ cell population compared
to control EBs (Figure 4b). The immunostaining of smooth
muscle cells has been performed with an antibody against
SMA, 1 day after plating the BMP2+ cells (7 + 1 days in total),
8 days after plating with puromycin (7 + 8 days in total), 18
days after plating with puromycin (7 + 18 days in total) and 18
days after plating without puromycin (7 + 18 days in total)
(Figure 4c). Detection of smooth muscle cells even 18 days
after puromycin treatment indicates that smooth muscle cells
express BMP2 and, therefore, survive the puromycin
treatment [65]. It is noteworthy that the number of SMA pos-
itive cells was less in the culture in which puromycin treat-
ment continued compared to the culture in which puromycin
treatment was discontinued. The inhibitory effect in these
cultures is more likely due to BMP2 since recent reports dem-
onstrated that BMP2 inhibits proliferation of smooth muscle
cells [66,67]. Simultaneously, the formation of smooth mus-
cle cells from their precursors is crucially dependant on the
phenotypic inductive role of BMP2 [68].
BMP2+ cells give rise to cardiomyocytes under EB 
conditions
The expression of the cardiac marker genes NKx2.5, MLC-2a,
α-cardiac actin and Mef2c is reduced in the BMP2+ cells com-
pared to the control EBs (Figure 5a,e). This suggests that
cardiomyogenesis is repressed in the BMP2+ cells. Accord-
ingly, Mesp1 was repressed (Figure 2a).
EBs prepared from a mixture of BMP2+ cells with wild-type
ES cells in ratios of 1:1, 1:2, 1:4, 10:1, 50:1, 1:10 and 1:50,
respectively (using the hanging drop protocol and applying
the differentiation protocol as outlined in Figure 5b and also
previously described [69]), did not augment/delay the onset
of contractile activity in comparison to control wild-type EBs
as observed on day 12. Also, there were no significant differ-
ences in terms of the magnitude of the intensity of the con-
tractility (data not shown). This corresponds to the
observation that BMP2 added during the differentiation of ES
cells did not enhance cardiomyogenesis [70]. Compared to
the CGR8 wild-type and β-actin control cells, culturing of the
BMP2+ cells for even a further 28 days (35 days in total) in the
presence or absence of puromycin did not result in beating
clusters of cardiac cells (data not shown). These results sug-
gest that the plated BMP2+ cells did not contain mature beat-
ing cardiomyocytes at this stage. In order to investigate the
cardiomyogenic potential of the BMP2+ cells to differentiate
into cardiac beating cells, EBs were made from the BMP2+
cells using the hanging drop protocol and the differentiation
process was observed in comparison to the EBs formed by
cells from control EBs. The secondary EBs made from the
BMP2+ cells were contracting on day 11, similarly to the sec-
ondary EBs formed by cells from seven-day-old control CGR8
wild-type EBs that were not treated with puromycin, as well
as EBs made from the β-actin CGR8 clone transfected with β-
actin  promoter-driven puromycin resistance and EGFP
expression cassettes that were treated with puromycin in the
same way as the secondary BMP2+ EBs. Notably, the intensity
of contraction in the BMP2+ EBs was significantly stronger
compared to that in both controls (Additional data file 10).
The whole EB was contracting in a jellyfish-like fashion
compared to the controls (Figure 5c; Additional data files 11
and 12). The contracting areas persisted for more than a week,
which was longer than in the control EBs. In order to investi-
gate whether the increased beating activity of the cardiomyo-
cytes generated from the BMP2+  cells correlates with
increased expression of cardiomyocyte specific transcripts,
we determined the expression of α-cardiac actin and α-MHC
in secondary EBs at day 11. Increased expression levels of
both cardiac specific genes was observed in the EBs generated
from BMP2+ cells compared to both the control secondary
EBs (Figure 5d). Thus, BMP2+  cells have the capacity to
develop into cardiomyocytes. Interestingly, the cardiomyo-
genic potential apparently seems to be regulated by the
BMP2+ lineage cells only. These findings suggest that the
BMP2+ cells are primed to become cardiomyocytes independ-
ently of the other, BMP2 negative lineage cells. However, nei-
ther the secondary EBs maintained on puromycin nor the
contractile secondary EBs when treated with puromycin con-
tained cardiomyocytes. The question of whether the cardio-
myocyte precursors contained in the BMP2+ cell population
are the transient derivatives of the NCSCs or another cell lin-
eage needs to be investigated, since NCSCs are also capable of
differentiating into cardiomyocytes [59,60]. However,
although the BMP2+ cells are capable of differentiating into
beating cardiomyocytes, further extensive investigations are
required to demonstrate the cardiogenic potential of these
cells in detail, as previously described for ES cell-derived car-
diomyocytes [71].
Vascular and haematopoietic cell gene markers from 
the BMP2+ cell population
Expression of E-cadherin, Flk1, Flt1, Pecam1 and Runx1
shows the presence of vascular endothelial progenitors in the
BMP2+ population (Figure 6a). As demonstrated in Figure 1j,
BMP2+ cells are able to differentiate into cells with an epithe-
lial/endothelial morphology after being cultured for eight
days in the presence of puromycin. Detection of epithelial-
like cells has been confirmed by immunostaining. As indi-
cated in Figure 6c, epithelial-like cells were detected even
after 11 days of culturing in the presence of puromycin.http://genomebiology.com/2007/8/9/R184 Genome Biology 2007,     Volume 8, Issue 9, Article R184       Doss et al. R184.19
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Expression of c-kit and CD34 and Runx1 indicates the pres-
ence of haematopoietic stem cells in the BMP2+ population
(Figure 6a,b). Ihh, which is implicated in haematopoiesis and
vasculogenesis [72] is also expressed in the BMP2+ cells but
its expression level is lower than that of the control cells. Flt-
1, also known as vascular endothelial growth factor receptor 1
(VEGFR-1), is a high-affinity tyrosine kinase receptor for vas-
cular endothelial growth factor and is normally expressed
only in vascular endothelial cells. However, the Flt-1 tran-
script was recently found to be expressed in human periph-
eral blood monocytes [73]. Monocytes are known to
differentiate into a variety of cell types, such as osteoclasts in
bone, dendritic cells in the immune system and mature mac-
rophages in a number of tissues, for example, Kupffer cells in
liver [73]. Expression of Flt-1 and c-fms in the BMP2+ popu-
lation indicates the possible existence of a monocyte-macro-
phage lineage in these cells.
BMP2+ cells give rise to osteoblasts and express gene 
markers for satellite cells and fibroblasts
Expression of osteopontin, Cbfa, osteocalcin and alkaline
phosphatase in BMP2+ cells showed the possible occurrence
of osteoblasts (Figure 7a). BMP2+ cells plated and maintained
in the differentiation medium with puromycin showed Ali-
zarin red positive clusters after 18 days (Figure 7b), which
indicates the first appearance of osteoblasts. After 35 days of
culturing in the presence of puromycin, areas brightly stained
with Alizarin red were observed, confirming the occurrence of
Differentiation of the BMP2+ cells to cardiac cells Figure 5
Differentiation of the BMP2+ cells to cardiac cells. (a) RT-PCR analysis of the cardiac markers in BMP2+ cells and other controls. (b) Schematic outline of 
the protocol used to derive cardiomyocytes from BMP2+ cells. (c) The morphology of the contracting EBs. The red arrows indicate the contracile area(s) 
in that EB. (d) RT-PCR analysis of the representative cardiac markers in 12 day secondary EBs derived by the hanging drop protocol from single cell 
suspension obtained from seven-day-old primary EBs generated by the protocol outlined in Figure 1 from CGR8 wild-type EBs without puromycin 
treatment, β-actin puro EGFP EBs and BMP2 EBs with puromycin treatment (videos of the beating clusters in these populations are provided as Additional 
data files 10-12). (e) Graph showing the relative expression levels of the genes presented in (a) as obtained by Affymetrix analysis. The expression levels of 
each gene were normalized with its maximum level set as 100%. Each result is an average of three independent experiments (Additional data file 13).
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osteoblasts in culture (Figure 7c). These results show that the
puromycin resistant BMP2+ cells per se are capable of differ-
entiating into osteoblasts. It may also be possible that the
osteoblasts might develop from the BMP2+ derived NCSCs in
the presence of an increased BMP2 concentration for longer
periods of time [74].
Expression of the transcription factor Sox9, the proteoglycan
aggrecan, and collagen II (with two alternative splicing
forms) was detected in the BMP2+ population, indicating the
existence of chondrocytes [75] (Figure 7a). Sox9 is a key
transcriptional factor for chondrocytic differentiation of mes-
enchymal cells via chondrocyte-specific enhancer of the pro
alpha1(II) collagen [76]. Expression of Pax-7 and myoD
shows the presence of satellite cells [77,78]. Satellite cells
represent a distinct lineage of myogenic progenitors respon-
sible for the maintenance of skeletal muscle [79]. MyoD is
expressed only when satellite cells are activated to proliferate
and differentiate into primary myoblasts, which will in turn
differentiate into cells of the myofibres of skeletal muscles
[78]. An elevated level of MyoD indicates either the prolifera-
tion or the differentiation of satellite cells into primary myob-
lasts in the BMP2+  population. But the expression of
myogenin and myostatin was not detected by RT-PCR, even
after 40 cycles in the BMP2+ cell population, suggesting the
absence of skeletal muscle cells. This hypothesis is supported
by Affymetrix data that show that myogenin is very weakly
expressed; myostatin (Gdf8) is not present on the Affymetrix
chip.
Interestingly, it has been reported that the satellite cells can
spontaneously differentiate into adipocytes in an alternative
mesenchymal pathway [80]. Expression of FSP-1 shows the
occurrence of fibroblasts in the BMP2+ cell population. FSP-1
has been implicated in the epithelial-mesenchymal transition
and is a representative marker for mesenchymal cells [81].
Analysis of the vascular and haematopoietic cell gene markers in the BMP2+ cell population Figure 6
Analysis of the vascular and haematopoietic cell gene markers in the BMP2+ cell population. (a) RT-PCR analysis of the BMP2+ cells. (b) Relative 
expression levels of the genes presented in (a) as obtained by Affymetrix analysis. The expression levels of each gene were normalized with its maximum 
level set as 100%. Each result is an average of three independent experiments (Additional data file 13). (c) Immunuostainings with anti-pan cytokeratin 
over the period of time to show the presence of epithelial like cells, from left to right: one day after plating the BMP2+ cells (7 + 1 days in total); 8 days 
after plating with puromycin (7 + 8 days in total); 18 days after plating with puromycin (7 + 18 days in total); and 11 days after plating without puromycin 
(7 + 11 days in total).
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Analysis of osteoblast, chondrocyte and myocyte specific markers in BMP2+ cells Figure 7 (see following page)
Analysis of osteoblast, chondrocyte and myocyte specific markers in BMP2+ cells. (a) RT-PCR analysis in BMP2+ cells. (b,c) Alizarin stanings on the 18th 
day after plating the BMP2+ cells (7 + 18 days in total) and 28 days after plating (7 + 28, 35 days in total). (d) Relative expression levels of the genes 
presented in (a) as obtained by Affymetrix analysis. The expression levels of each gene were normalized with its maximum level set as 100%. Each result is 
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The BMP2+ cell lineage contains monocytes but not 
mature adipocytes
The RT-PCR analysis of the BMP2+ population showed the
expression of the pre-adipocyte gene marker pref-1 [82], the
pan-adipocyte markers PPARγ [83], aP2, Glut4 [84] and LPL
as well as the pan-macrophage marker c-fms [82,83,85]
(Figure 8a,b). Although the markers PPARγ, aP2 and Glut4
are unique to adipocytes, these genes are also expressed in
macrophages. Similarly, the trophoblast lineage also
expresses c-fms [82]. Notably, the cells derived from the
BMP2+ cells cultured in the continual presence of puromycin
were not positive for either Sudan Red or anti F4/80 stain-
ings. However, when puromycin treatment was discontinued,
there were cells stained with Sudan Red and F4/80, a marker
for macrophages, as shown in Figure 8c,d. These findings
suggest that macrophages are derived from differentiated
BMP2+ cells in which BMP2 expression is downregulated at a
later time. There were no cells stained with Oil Red O in both
cases (with discontinued puromycin treatment), even when
cultured for a prolonged period of days. Thus, the BMP2+
population might contain the pre-adipocytes expressing only
PPARγ, aP2, Glut4 and Pref-1 but not adipsin. Apparently,
other factors secreted by BMP2 negative cells are required for
maturation of pre-adipocytes to adipocytes.
Conclusion
The in vitro ES-derived BMP2+ population contains trophec-
toderm, NCSCs and their derivatives - smooth muscle cells,
pericytes, melanocytes, cardiomyocytes as well as vascular
and haematopoietic progenitors. Enrichment of the neural
crest cells and their lineages by BMP2 promoter-driven selec-
tion markers paves the way for ES cell-derived neural crest
stem cell biology. These cells are attractive candidates for
future cell replacement therapies due their ability to
diferentiate into any tissue depending upon the local
environment within the injected tissue. Furthermore, we
showed that the increased developmental potential of the
BMP2+ expressing cells is accompanied by increased tran-
scriptional and apoptotic activity. Finally, the identification
of the genes that are specifically expressed in the BMP2+ pop-
ulation will contribute to a gene expression atlas for mesoder-
mal developmental genes that will be useful for further
studies to elucidate their role during developmental
processes.
Materials and methods
ES cell culture and differentiation of EBs
Murine CGR8 ES cells (ECACC 95011018) were cultured in
the absence of feeder cells in Glasgow minimum essential
medium (GMEM) supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine, 100 units/ml leukemia inhibitory
factor (LIF) and 50 μM  β-mercaptoethanol (ME) in 0.2%
gelatine coated flasks as previously described [69]. To induce
differentiation, an ES cell suspension of 1.6 × 104 cells/ml was
made in Iscove's modified Dulbecco's Medium (IMDM) sup-
plemented with 20% (FBS), 1% non-essential amino acids
(vol/vol), 2 mM L-glutamine and 100 μM β-ME. The cells
were cultured in bacteriological dishes for two days, then the
two-day-old EBs were transferred into a 0.2% gelatine coated
10 cm tissue culture dish. On day 4, the EBs were treated with
3 μg/ml puromycin for the next 3 days. Medium containing
puromycin was refreshed every day. On day 7, the puromycin
resistant BMP2+ cells were used for the experiments.
The hanging drop differentiation protocol as described in Fig-
ure 1 was carried out as follows. Briefly, 500 undifferentiated
BMP2+ ES cells were spotted in 20 μl differentiation medium
in the upper lid of a bacteriological dish and cultured for 2
days. On day 2, the EBs were transferred into suspension
until assays were performed, with medium changes in
between as outlined in Figure 5b.
Vector construct and cell line generation
pIRES2 EGFP was purchased from Clontech (Heidelberg,
Germany). Human cytomegalovirus (CMV) immediate early
promoter and enhancer were removed by a double digestion
with NheI and AseI and then subsequently blunt end ligated
to get the pIRES2 EGFP φ CMV construct. Puromycin cDNA
flanked on both ends by BamH1 restriction sites, which was
PCR amplified from pIRESPuro3 by Pfu  DNA polymerase
(Promega, Mannheim, Germany), was inserted at the SmaI
site of the pIRES2 EGFP φ CMV construct to get pPuro IRES2
EGFP. A 2.9 kb BMP2 promoter fragment with both proximal
and distal transcription start sites, excised with HindIII and
SacI digestion from pBMP2-GL3 [86], were blunt end ligated
to  EcoRI digested and klenowed pPuro IRES2 EGFP to
generate pBMP2p Puro IRES2 EGFP. This BMP2 reporter
construct drives the expression of both puromycin resistance
and EGFP under the control of the BMP2 promoter by the use
of an IRES sequence. This construct was electroporated in
CGR8 with 500 μF and 240 V in a Bio-Rad Gene Pulser™
(Bio-Rad, Hercules, CA, USA). The transfected clones were
selected using 400 μg/ml neomycin and, after selection, were
maintained with 200 μg/ml neomycin. During EB genera-
tion, the neomycin selection was discontinued.
Immunohistochemistry
One day prior to the sample processing, 50,000 cells per each
well of Lab-Tek Permanox slide Chambers (Nalge Nunc Inter-
national, Naperville, IL, USA) were seeded and cultured in
the absence of puromycin. After 24 hours, the samples were
fixed with either 4% paraformaldehyde in phosphate-buff-
ered saline for 10 minutes or -20°C precooled methanol-ace-
tone (1:1) solution, permeabilized with 0.1% Triton X-100,
and labeled with the following antibodies: mouse anti-SMA
(1:200) (Sigma, Taufkirchen, Germany); mouse anti-pan
cytokeratin (1:50) (DakoCytomation, Hamburg, Germany);
mouse anti-Ksp-cadherin (Zymed, South San Francisco, CA,
USA); mouse anti-myoD1 (Santa Cruz, Heidelberg, Ger-
many); anti-actinin antibodies (Sigma, Taufkirchen, Ger-http://genomebiology.com/2007/8/9/R184 Genome Biology 2007,     Volume 8, Issue 9, Article R184       Doss et al. R184.23
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many); mouse anti-GFAP (1:100) (Sigma, Taufkirchen,
Germany); rabbit anti-p75 NTR (1:100), (Chemicon, Hamp-
shire, UK); rabbit anti-S100 (1:400), (DakoCytomation,
Hamburg, Germany); and mouse anti-actinin (1:100). This
was followed by labeling with secondary antibodies, either
Cy3-labeled anti-rabbit IgG (Sigma), rhodamine labeled anti-
mouse IgG (Sigma), or Cy3-labeled donkey anti-rat IgG
antibodies. The specificity of the antibodies has been tested
using the appropriate tissues (Additional data file 13). For a
control of SMA immunostaining, vessels of mouse liver were
stained. Heart and skeletal muscles of embryonic mouse tis-
sues served as controls for the specifity of the anti-actinin and
the myoD1 antibodies, and murine brain tissue for the speci-
fity of antibodies against neuronal markers such as p75-NTR
Analysis of adipocyte and macrophage associated markers in BMP2+ cells Figure 8
Analysis of adipocyte and macrophage associated markers in BMP2+ cells. (a) RT-PCR analysis of adipocyte specific markers. (b) Relative expression levels 
of the genes presented in (a) as obtained by Affymetrix analysis. The expression levels of each gene were normalized with its maximum level set as 100%. 
Each result is an average of three independent experiments (Additional data file 13). (c) Sudan red staining on 11-day-old puromycin untreated culture 
after plating the BMP2+ cells (7 + 11, 18 days in total). (d) F4/80 immunuostaining on 18-day-old puromycin untreated culture after plating BMP2+ cells (7 
+ 18, 25 days in total).
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and GFAP. Mouse kidney and small intestine were used as
control tissues for Ksp-cadherin or E-cadherin and pan-cyok-
eratin staining, respectively.
Sudan Red and Alizarin Red S stainings
Sudan Red staining was performed on paraformaldehyde
fixed embryonic cell clusters or on cytospins of human lym-
phocytes. The paraformaldehyde-fixed samples were treated
with Alizarin Red S for five minutes and then excess Alizarin
Red was washed off by dipping in acetone:xylene (1:1), fol-
lowed by a wash in xylene. They were then stained for haema-
toxylin for ten minutes and the excess dye was washed off in
running water.
Semiquantitative RT-PCR analysis
Total RNA was extracted using RNeasy Mini Kit (Qiagen,
Hilden, Germany) with on-column DNase I (Qiagen) diges-
tion according to the manufacturer's instructions. Total RNA
(5 μg) was reverse transcribed using SuperScript II Reverse
transcriptase (Invitrogen GmbH, Karlsruhe, Germany) with
random primers according to the manufacturer's recom-
mended protocol. PCR amplification was done with REDTaq
ReadyMix (Sigma) with 0.4 μM of each primer. GAPDH was
used as an internal control. The following conditions were
used. An initial denaturation at 95°C for 2 minutes, followed
by 22-35 cycles of 30 s denaturation at 95°C, 30 s annealing
at 60°C and 60 s of elongation at 72°C. A final extension at
72°C for 5 minutes was included. Electrophoretic separation
of PCR products was carried out on 2% agarose gels with
0.001% ethidium bromide. The primer pairs included in this
study are listed in Additional data file 14.
Flow cytometry
A single cell suspension was prepared by trypsinization. Cell
clumps were removed by passing through the cell strainer cap
of a round bottom tube from BD Falcon® (Heidelberg, Ger-
many). Propidium iodide staining (Sigma) was included to
exclude dead cells. Acquisition of 10,000 live (PI negative)
cells was done with a FACScan (BD Biosciences, Heidelberg,
Germany) and the data analysis was done with CellQuest soft-
ware (Becton Dickinson, Heidelberg, Germany). The wild-
type EBs were used as the control on the same day as the sam-
ple EBs.
Affymetrix analysis
Total RNA was extracted from undifferentiated ES cells and
EBs using the RNeasy total RNA isolation kit (Qiagen GmbH,
Hilden, Germany). The preparation quality was assessed by
agarose formaldehyde gel electrophoresis. Three independ-
ent total RNA preparations, each 15 μg from the BMP2+ cells,
the mixed cell population and the undifferentiated ES cells,
were labelled with the One-Cycle Target Labeling and Control
Reagent package (Affymetrix, High Wycombe, UK) as
described in the manufacturer's instructions. Briefly, double-
stranded cDNA was synthesized using the one-cycle cDNA
synthesis module. Biotinylated cRNA was synthesized with
the IVT labeling kit and cleaned up using the sample cleanup
module.
After fragmenting of the cRNA for target preparation using
the standard Affymetrix protocol, 15 μg fragmented cRNA
was hybridized for 16 h at 45°C to Mouse Genome 430 2.0
arrays, which carry probe sets representing 45,101 probe sets.
Following hybridization, arrays were washed and stained
with streptavidin-phycoerythrin in the Affymetrix Fluidics
Station 450 and further scanned using the Affymetrix Gene-
Chip Scanner 3000 7G. The image data were analyzed with
GCOS 1.4 using Affymetrix default analysis settings. After
RMA normalization [87], three pair-wise comparisons were
performed using the Student's t-test (unpaired, assuming
unequal variances). A Student's t-test p value < 10-2 and a fold
change >2 were used to identify and restrict the number of
differentially expressed genes. Hierarchical clustering was
performed for an intersection of genes differentially
expressed between undifferentiated BMP2 ES cells and
BMP2+ EBs as well as differentially expressed between seven-
day-old control EBs and BMP2+ EBs (three condition com-
parative analysis) to determine and differentiate treatment
and developmental aspects. The cluster analysis (see Addi-
tional data file 9, part E) was done using cluster version 2.11
[88], applying mean-centering and normalization of genes
and arrays before average linkage clustering with uncentered
correlation.
Functional annotation
Differentially expressed genes were analyzed according to
predefined pathways or functional categories annotated by
KEGG [11], BioCarta [12], and GO [10] using the DAVID bio-
informatic resource [29]. For an overrepresented GO, Bio-
carta or KEGG pathway, a cut-off p value of 0.1 was chosen. In
general, it should be noted that one gene can participate in
more than one KEGG or BioCarta pathway or GO category.
Quantitative real-time PCR
Validation of the Affymetrix data was performed by qPCR
analysis with the ABI Prism 7900 HT Sequence Detection
System (Applied Biosystems, Foster City, CA, USA). RNA (1
μg) from BMP2 ES cells, seven-day-old control EBs and
BMP2+ cells were reverse transcribed with ThermoScript™
Reverse Transcriptase (Invitrogen). Then, qPCR was per-
fomed in triplicate for every sample using TaqMan Gene
Expression Assays (Applied Biosystems). The Gene Expres-
sion Assays used for validation were Brachyury (T)
(Mm00436877_m1), NF-H (Mm01191456_m1), BMP2
(Mm01340178_m1), GAPDH (Mm99999915_g1), and Nanog
(Mm02019550_s1). Averaged Ct values of each qPCR reaction
from the target gene were normalized with the average Ct val-
ues of the housekeeping gene, GAPDH, which ran in the same
reaction plate, to obtain the ΔCt value. The fold change was
calculated as follows: fold change =  .
Since the genes included are not expressed in at least one of
the three conditions (BMP2 ES cells, seven-day-old control
2
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EBs or BMP2+ cells), the ΔCt of the gene in the sample with the
lowest expression was used as ΔCt gene2 to calculate the fold
change using the above formula. The resulting fold change is
expressed as the percentage of the maximum fold change.
Abbreviations
AFP,  α-feto protein; BMP, bone morphogenetic protein;
CMV, cytomegalovirus; EB, embryoid body; ECM, extracellu-
lar matrix; EGFP, enhanced green fluorescent protein; ES,
embryonic stem; FACS, fluorescence activated cell sorting;
FGF, fibroblast growth factor; GFAP, glial fibrillary acidic
protein; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of
Genes and Genomes; LIF, leukemia inhibitory factor; MAPK,
mitogen activated protein kinase; NCSC, neural crest stem
cell; NF, neurofilament; qPCR, quantitative real time PCR;
Shh, Sonic Hedgehog; SMA, smooth muscle α actin; TGF,
transforming growth factor.
Authors' contributions
AS, MXD and JH designed the study. MXD and RHA per-
formed the experiments. SB, MO and CW did immunohisto-
chemical analysis. SC, JW, HS, IS, OH and NH did the
Affymetrix analysis. MXD, JW, SC and AS wrote the manu-
script. NGC provided the BMP2 promoter for this study.
Additional data files
The following additional data are available with the online
version of this manuscript: Additional data file 1 contains the
RT-PCR analysis of differentiating EBs derived from the
BMP2 ES cells. Additional data file 2 shows the validation of
Affymetrix expression profiling data by quantitative real-time
PCR. Additional data file 3 provides a list of transcripts
belonging to the GO category 'transcription' that are upregu-
lated at least two-fold in the BMP2+ cells. Additional data file
4 provides a list of transcripts belonging to the GO category
'apoptosis' that are upregulated least two-fold in the BMP2+
cells. Additional data file 5 provides a list of transcripts
belonging to the MAPK signaling pathway that are upregu-
lated in the BMP2+ cells as well as a schematic of the KEGG
MAP kinase signaling pathway indicating the genes upregu-
lated in the BMP2+ cells. Additional data file 6 provides a list
of transcripts belonging to the GO category 'development'
that are downregulated at least two-fold in the BMP2+ cells
compared to the control cells in the seven-day-old EBs.
Additional data file 7 provides a list of transcripts belonging
to the TGF-β signaling pathway that are specifically upregu-
lated in the BMP2+ cells as well as a schematic of the KEGG
TGF-β signaling pathway indicating the upregulated genes.
Additional data file 8 provides a list of transcripts belonging
to the GO category 'M phase' that are specifically upregulated
in the BMP2+ cells. Additional data file 9 shows selected GO
Table 6
Functional annotations (GO, KEGG, Biocarta) enriched in transcripts downregulated* in BMP2+ cells compared to control cells in seven-
day-old EBs and to undifferentiated BMP2 ES cells
Category Term Count p value
GOTERM_BP_5 DNA metabolism 15 8.4E-5
GOTERM_BP_5 M phase of mitotic cell cycle 7 5.2E-4
GOTERM_BP_5 Carboxylic acid metabolism 11 2.8E-3
GOTERM_CC_5 Chromosome 9 3.8E-3
GOTERM_BP_5 Biopolymer modification 22 9.4E-3
GOTERM_MF_5 Pyrophosphatase activity 10 9.5E-3
GOTERM_BP_5 Amino acid metabolism 6 3.2E-2
GOTERM_BP_5 Recombinational repair 2 3.9E-2
GOTERM_BP_5 Cellular protein metabolism 31 4.2E-2
GOTERM_CC_5 Heterotrimeric G-protein complex 3 4.3E-2
GOTERM_MF_5 Metalloendopeptidase activity 4 5.0E-2
GOTERM_CC_5 Chromosome, periventric region 3 5.9E-2
GOTERM_CC_5 Condensed chromosome 3 6.4E-2
GOTERM_BP_5 Lipid biosynthesis 5 7.5E-2
KEGG_PATHWAY Pyruvate metabolism 3 7.7E-2
GOTERM_BP_5 Steroid biosynthesis 3 8.3E-2
GOTERM_BP_5 Double-strand break repair 2 8.4E-2
GOTERM_BP_5 Regulation of smooth muscle contraction 2 8.4E-2
GOTERM_MF_5 Phosphoric hydrolase activity 3 9.4E-2
GOTERM_MF_5 AMP binding 2 9.7E-2
*Fold change >2, Student's t-test p value < 0.01. Count indicates the number of genes in the functional annotation category. The p value is from gene 
enrichment in annotation terms calculated by the Fisher's exact t-test.R184.26 Genome Biology 2007,     Volume 8, Issue 9, Article R184       Doss et al. http://genomebiology.com/2007/8/9/R184
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annotations and clustering results of genes differentially
expressed in BMP2+ cells. Additional data file 10 provides a
video clip of β-actin CGR8 cardiomyocytes. Additional data
files 11 and 12 provide video clips of BMP2+ cell-derived car-
diomyocytes without and with green filter, respectively. Addi-
tional data file 13 shows the immunohistochemistry results
for the positive controls. Additional data file 14 contains the
primers used for RT-PCR analysis. Additional data file 15 pro-
vides the normalized Affymetrix dataset of all experimental
conditions, representing three independent experiments.
Additional data file 16 provides the normalized Affymetrix
data set for the probe sets identified to be differentially down-
regulated in BMP2+ cells compared to control EBs. Additional
data file 17 provides the normalized Affymetrix dataset for the
probe sets identified to be differentially downregulated in
BMP2+ cells compared to control EBs and compared to undif-
ferentiated BMP2 ES cells. Additional data file 18 provides
the normalized Affymetrix dataset for the probe sets
identified to be differentially upregulated in BMP2+  cells
compared to control EBs Additional data file 19 provides the
normalized Affymetrix dataset for the probe sets identified to
be differentially upregulated in BMP2+ cells compared to con-
trol EBs and compared to undifferentiated BMP2 ES cells.
Additional data file 1 RT-PCR analysis of differentiating EBs derived from the BMP2 ES  cells EBs were generated using the conventional hanging drop protocol  (see Materials and methods and Figure 5b) and the expression of  the T-bra, flk1, smooth muscle α-actin, cardiac Troponin T (c-Tro- ponin T), NF-H, NF-M and AFP was detected using RT-PCR (for  the conditions, see Additional data file 14). Click here for file Additional data file 2 Validation of Affymetrix expression profiling data by quantitative  realtime PCR The fold change of the expression of the genes was calculated by  using the formula: fold-change = . The ΔCt of a gene in the sample  in which it is expressed at the lowest level is taken as ΔCt gene2 to  calculate the fold change using the above formula. The resulting  fold change is expressed as the percentage of the maximum fold  change (100%) for that particular gene in every assay. Values are  expressed as mean ± standard deviation (n = 3, technical repli- cates). Click here for file Additional data file 3 Transcripts belonging to the GO category 'transcription' that are  upregulated at least two-fold in the BMP2+ cells Transcripts belonging to the GO category 'transcription' that are  upregulated at least two-fold (t-test p value < 0.01) in the BMP2+  cells compared to the control cells in the seven-day-old EBs, and  those upregulated compared to the control cells in the seven-day- old EBs and the undifferentiated BMP2 ES cells. Click here for file Additional data file 4 Transcripts belonging to the GO category 'apoptosis' that are  upregulated at least two-fold in the BMP2+ cells Transcripts belonging to the GO category 'apoptosis' that are  upregulated at least two-fold (t-test p value < 0.01) in the BMP2+  cells compared to the control cells in the seven-day-old EBs, and  those upregulated compared to the control cells in the seven-day- old EBs and the undifferentiated BMP2 ES cells. Click here for file Additional data file 5 Transcripts belonging to the MAPK signaling pathway that are  upregulated at least two-fold in the BMP2+ cells Transcripts belonging to the MAPK signaling pathway that are  upregulated at least two-fold (t-test p value < 0.01) in the BMP2+  cells compared to the control cells in the seven-day-old EBs, and  those upregulated compared to the control cells in the seven-day- old EBs and the undifferentiated BMP2 ES cells. The schematic is  of the KEGG MAP kinase signaling pathway, indicating the upreg- ulated genes (labelled with red background) in the BMP2+ cells  compared to the control cells in the seven-day-old EBs. Click here for file Additional data file 6 Transcripts belonging to the GO category 'development' that are  downregulated at least two-fold in the BMP2+ cells compared to the  control cells in the seven-day-old EBs Transcripts belonging to the GO category 'development' that are  downregulated at least two-fold (t-test p value < 0.01) in the  BMP2+ cells compared to the control cells in the seven-day-old EBs. Click here for file Additional data file 7 Transcripts belonging to the TGFβ signaling pathway that are spe- cifically upregulated at least two-fold in the BMP2+ cells compared  to the control cells in the seven-day-old EBs as well as a schematic  of the KEGG TGFβ signaling pathway indicating the upregulated  genes Transcripts belonging to the TGFβ signaling pathway that are spe- cifically upregulated at least two-fold (t-test p value < 0.01) in the  BMP2+ cells compared to the control cells in the seven-day-old EBs  as well as a schematic of the KEGG TGFβ signaling pathway indi- cating the upregulated genes (labelled with red background and  white letters). Click here for file Additional data file 8 Transcripts belonging to the GO category 'M phase' that are specif- ically upregulated in the BMP2+ cells Transcripts belonging to the GO category 'M phase' that are specif- ically upregulated at least two-fold (t-test p value < 0.01) in the  BMP2+ cells compared to the control cells in the seven-day-old EBs  and to the undifferentiated BMP2 ES cells. Click here for file Additional data file 9 Selected GO annotations of genes differentially expressed in  BMP2+ cells (A,B) Pairwise comparison (BMP2 versus control EBs): 2,258  probeset IDs that were differentially expressed in BMP2+ cells com- pared to control EBs (two-condition comparison) were converted  to GenBank accession numbers and redundancies were removed  (1,833 unique transcripts). Stanford Source was used to obtain GO  biological process (BP) annotations. Genesis 1.7.0 was used to vis- ualize and identify GO BP categories of interest and extract corre- sponding lists of transcripts. For the categories adhesion, cell cycle,  cell death, cell-cell signaling, cellular metabolism, development,  stress response, signal transduction, transcription and transport,  1,541 annotations were established for 1,172 transcripts. The pie  chart (A) shows the distribution of these annotations. The bar chart  (B) shows the number of genes in the categories adhesion, cell  cycle, cell death, cell-cell signaling, cellular metabolism, develop- ment, stress response, signal transduction, transcription and trans- port separately for up- and downregulated transcripts. (C,D)  Three-condition comparison (BMP2 versus control EBs and BMP2  ES cells). For the three-condition comparison, 551 unique tran- scripts were obtained from 672 probeset IDs that were differen- tially expressed in BMP2 versus control EBs and versus  undifferentiated BMP2 ES cells using the approach described  above. For the categories adhesion, cell cycle, cell death, cell-cell  signaling, cellular metabolism, development, stress response, sig- nal transduction, transcription and transport, 430 annotations  were established for 268 transcripts. The pie chart (C) shows the  distribution of these annotations. The bar chart (D) shows the  number of genes in the categories adhesion, cell cycle, cell death,  cell-cell signaling, cellular metabolism, development, stress  response, signal transduction, transcription and transport sepa- rately for up- and downregulated transcripts. (E) Clustering analy- sis of the probesets identified as differentially expressed in the two- condition comparison (see A) and assigned to the GO category  'development'. Expression data were normalized using the RMA  algorithm and hierarchical clustering was done using Cluster 2.11  as described. Visualization of the hierarchical clustering of probe  sets identified as differentially expressed in the pairwise compari- son (see A) and assigned to the GO category 'development'. Each  probe set is represented by a single column of colored boxes; each  array is represented by a single row. Cells with unchanged probe  sets are colored black, upregulation is indicated with reds of  increasing intensity, and downregulation with greens of increasing  intensity. The dendrogram on the top of the figure represents the  similarity matrix of probe sets, the dendrogram to the right the  similarity matrix of arrays. Click here for file Additional data file 10 A video clip of β-actin CGR8 cardiomyocytes A video clip of β-actin CGR8 cardiomyocytes. Click here for file Additional data file 11 A video clip of BMP2+ cell-derived cardiomyocytes without green  filter A video clip of BMP2+ cell-derived cardiomyocytes without green  filter. Click here for file Additional data file 12 A video clip of BMP2+ cell-derived cardiomyocytes with green filter A video clip of BMP2+ cell-derived cardiomyocytes with green filter. Click here for file Additional data file 13 Immunohistochemistry results for the positive controls (A) Anti-SMA staining on mouse liver tissue. (B) MyoD1 on mouse  embryonic sections. (C) α-Actinin on embryonic cardiac tissue of  mouse. (D) F4/80 staining on mouse skin sections. (E) Pan cytok- eratin on small intestine of mouse. (F) Ksp-Cadherin on mouse kid- ney sections. (G) GFAP on rat brain sections. (H) E-cadherin on  mouse kidney sections. (I) Alizarin Red staining on human limb  bone sections. (H) Sudan Red stainings on cytospin leukocytes. Click here for file Additional data file 14 Primers used for RT-PCR analysis Primers used for RT-PCR analysis. Click here for file Additional data file 15 Normalized Affymetrix dataset of all experimental conditions Complete Affymetrix dataset for all experimental conditions, rep- resenting three independent experiments. Data were RMA-nor- malized as described in Materials and methods. For each probe set,  the average expression value and standard deviations are given  (columns B-G) as well as the change fold between conditions (col- umns H-J) and the results of Student's t-test between the experi- mental conditions (K-M). Expression values for the individual  experimental replicates are provided in columns N-V. Click here for file Additional data file 16 Normalized Affymetrix data set for the probe sets identified to be  differentially downregulated in BMP2+ cells compared to control  EBs Normalized Affymetrix data set for the probe sets identified to be  differentially downregulated in BMP2+ cells compared to control  EBs (higher than two-fold downregulation, t-test p value < 0.01). Click here for file Additional data file 17 Normalized Affymetrix dataset for the probe sets identified to be  differentially downregulated in BMP2+ cells compared to control  EBs and undifferentiated BMP2 ES cells Normalized Affymetrix dataset for the probe sets identified to be  differentially downregulated in BMP2+ cells compared to control  EBs and undifferentiated BMP2 ES cells (intersection of downreg- ulation in BMP2+ cells compared to control EBs (higher than two- fold downregulation, t-test p value < 0.01) and compared to undif- ferentiated BMP2 ES cells (higher than two-fold downregulation, t- test p value < 0.01)). Click here for file Additional data file 18 Normalized Affymetrix dataset for the probe sets identified to be  differentially upregulated in BMP2+ cells compared to control EBs Normalized Affymetrix dataset for the probe sets identified to be  differentially upregulated in BMP2+ cells compared to control EBs  (higher than two-fold upregulation, t-test p value < 0.01). Click here for file Additional data file 19 Normalized Affymetrix dataset for the probe sets identified to be  differentially upregulated in BMP2+ cells compared to control EBs  and compared to undifferentiated BMP2 ES cells Normalized Affymetrix dataset for the probe sets identified to be  differentially upregulated in BMP2+ cells compared to control EBs  and compared to undifferentiated BMP2 ES cells (intersection of  upregulation in BMP2+ cells compared to control EBs (higher than  two-fold upregulation, t-test p value < 0.01) and compared to  undifferentiated BMP2 ES cells (higher than two-fold upregula- tion, t-test p value < 0.01)). Click here for file
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